Author for correspondence:
Chai Molina
e-mail: cmgraff@gmail.com

THE ROYAL SOCIETY
PUBLISHING

Game theory of pre-emptive vaccination before bioterrorism or accidental release of smallpox

Chai Molina[1] and David J. D. Earn[1,2]

[1]Department of Mathematics and Statistics, and [2]M.G. deGroote Institute for Infectious Disease Research, McMaster University, Hamilton, Ontario, Canada L8S 4K1

Smallpox was eradicated in the 1970s, but new outbreaks could be seeded by bioterrorism or accidental release. Substantial vaccine-induced morbidity and mortality make pre-emptive mass vaccination controversial, and if vaccination is voluntary, then there is a conflict between self- and group interests. This conflict can be framed as a tragedy of the commons, in which herd immunity plays the role of the commons, and free-riding (i.e. not vaccinating pre-emptively) is analogous to exploiting the commons. This game has been analysed previously for a particular post-outbreak vaccination scenario. We consider several post-outbreak vaccination scenarios and compare the expected increase in mortality that results from voluntary versus imposed vaccination. Below a threshold level of post-outbreak vaccination effort, expected mortality is independent of the level of response effort. A lag between an outbreak starting and a response being initiated increases the post-outbreak vaccination effort necessary to reduce mortality. For some post-outbreak vaccination scenarios, even modest response lags make it impractical to reduce mortality by increasing post-outbreak vaccination effort. In such situations, if decreasing the response lag is impossible, the only practical way to reduce mortality is to make the vaccine safer (greater post-outbreak vaccination effort leads only to fewer people vaccinating pre-emptively).

1. Introduction

The number of annual cases of smallpox in the early 1950s, just prior to the World Health Organization's global eradication programme, is estimated at 50 million [1]. The eradication campaign was successful [1], but samples of the variola virus are still kept in at least two known laboratories in Russia and the USA [2]. In a worrying incident in July 2014, previously forgotten vials containing samples of smallpox, some of which were viable, were found in a laboratory at the National Institutes of Health campus in Bethesda, MD, USA [3]. Thus, the threat of the reintroduction of smallpox, whether inadvertently or in a bioterrorist attack, is still present.

Consequently, some countries—notably the USA—are interested in measures to protect their populations from potential smallpox infection. Prophylactic vaccination for smallpox carries a high cost (relative to other vaccines in use today), as the probability of death following vaccination—or 'risk from being vaccinated'—is $r_v \simeq 10^{-6}$ and serious side-effects occur with probability $\sim 10^{-3}$ [1]. Of course, infection with smallpox carries a much greater risk, because the case fatality proportion—the 'risk from infection'—is $r_i \simeq 0.3$ [1]. (See table 1 for a summary of parameter estimates.)

The substantial vaccine-induced morbidity and mortality associated with smallpox vaccination make pre-emptive mass vaccination controversial. If vaccination is voluntary, then there is a conflict between self- and group interests. This conflict can be framed as a tragedy of the commons, in which herd immunity plays the role of the commons, and free-riding (i.e. not vaccinating pre-emptively) is analogous to exploiting the commons. A previous game-theoretical study by Bauch *et al.* [4] examined this conflict of interest, and focused on the trade-off between prophylactic vaccination and post-outbreak mass vaccination (which has been shown to outperform contact-traced vaccination in a bioterrorism setting

Table 1. Summary of the fundamental (i.e. not derived) numerical parameters in our analysis, together with estimated values. Note that in [4] the probability of an outbreak was denoted r rather than a. Here, we use r for the relative risk, as in [5]. The proportion of the population infected initially by a bioterrorist attack or accidental release, α, corresponds to infection of 5000 individuals in a population of 290 million (after [4]).

quantity	interpretation	value	source
r_v	mortality risk from vaccination (probability)	10^{-6}	[4]
r_i	mortality risk from infection (probability)	0.3	[4]
$\mathcal{R}_0$	basic reproductive ratio	5	[6–8]
t_{ser}	mean serial interval	22 days	[9, p. 141]
$1/\sigma$	mean latent period (SEIRV)	15 days	[1, p. 188] and [4]
$\phi_{\langle model \rangle}$	vaccination effort parameter (exact interpretation depends on model)	see table 4	
t_{lag}	response lag before initiation of post-outbreak vaccination	0 days, except in §7.5	
a	probability of attack or accidental release per lifetime	0.01	[4]
α	proportion of susceptibles initially infected in an outbreak	$5000/290 \times 10^6 \simeq 1.72 \times 10^{-5}$	[4]

Table 2. Summary of derived parameters.

quantity	interpretation	value
$r = r_v/r_i$	relative risk (from being vaccinated compared with natural infection)	$10^{-6}/0.3 \simeq 3.33 \times 10^{-6}$
$1/\gamma$	mean time infectious (SIRV)	$t_{ser} = 22$ days
$1/\gamma$	mean time infectious (SEIRV)	$t_{ser} - (1/\sigma) = 7$ days
β	transmission rate	$\gamma\mathcal{R}_0$
π_p	probability that an un-vaccinated individual will eventually be infected if the vaccine coverage level in the population is p	derived from epidemic model in §5
ψ_p	probability of an individual un-vaccinated at the beginning of the epidemic becoming vaccinated, given vaccine coverage level p	derived from epidemic model in §5

[10]). In particular, they showed that if the decision regarding pre-emptive vaccination is left to the individual, then the vaccine coverage achieved will be suboptimal from the group perspective. Bauch *et al.* [4] assumed that, once a post-outbreak vaccination campaign begins, individuals will be vaccinated at a constant rate determined by existing infrastructure.

Various mechanisms might drive the rate of vaccination. Vaccination at a constant rate might be achieved if vaccination centres are flooded by individuals seeking the vaccine, and are operating at peak capacity. However, public responsiveness to such a campaign is hard to predict. If demand for the vaccine does not exceed the maximal rate of distribution by public health services, the post-outbreak dynamics might play out differently, depending on the public's reaction patterns. For example, media reports on the number of new cases might influence individuals to obtain the vaccine; in that case, it is reasonable to model the vaccination rate as proportional to smallpox incidence.

In this paper, we return to the problem posed by Bauch *et al.* [4], but compare a variety of possible post-outbreak vaccination scenarios (described intuitively in §2 and in precise mathematical terms in §5). Whereas the scenario considered in [4] could only be analysed numerically, several of the vaccination scenarios that we consider here can be addressed analytically to obtain exact results. To this end, in §3, we make some adjustments to the game-theoretical framework of Bauch & Earn [5], so that it can be applied to the scenarios we investigate here.

Throughout this paper, we use smallpox as an illustrative example. However, our analyses can be applied to any vaccine-preventable infectious disease that could be used for bioterrorism or released accidentally, and for which the susceptible–infectious–removed (SIR) or susceptible–exposed–infectious–removed (SEIR) models are applicable (see §5). Our qualitative results appear to be robust to which post-outbreak vaccination scenario is considered and the specific parameter values (we prove this in some cases), but the precise numerical values will vary.

We calculate the vaccination coverage obtained by voluntary pre-emptive vaccination and assess the costs of this policy when compared with mandatory vaccination. The group-optimal pre-emptive vaccine coverage is discussed in §4. We discuss parameter estimates and the procedure used to compare the various models fairly in §6. We compare the predictions of the various models, and emphasize important considerations for public health in §7. Notation and definitions are summarized in tables 1–3.

2. Vaccination scenarios

In this section, we give a brief description of the various post-outbreak vaccination scenarios considered in this paper.

Media coverage of a smallpox outbreak is likely to influence individual decisions concerning vaccination. Measures of severity of the outbreak that are likely to appear in the media include:

— death rates, as in '300 people died of smallpox today',
— total number of people currently infected (prevalence), as in 'there are now 30 000 people sick with smallpox', and

Table 3. Summary of other notation.

quantity	interpretation
P	probability that an individual chooses to vaccinate pre-emptively (this defines the individual's strategy)
p	pre-outbreak vaccine coverage (proportion of the population vaccinated pre-emptively)
p_g	the group optimum, i.e. the proportion of the population vaccinated pre-emptively which minimizes mortality
p_i	the individual equilibrium, i.e. the level of pre-outbreak vaccine coverage which is the unique Nash equilibrium, as described in §3
$C(p)$	the mortality cost, i.e. the proportion of the population that is expected to die, given pre-emptive vaccine coverage p
t_{lag}^*	the critical lag, i.e. the response lag beyond which mortality is independent of vaccination effort (see §7.5.1)
t_{lag}^{**}	the effective critical lag, i.e. the response lag beyond which mortality is identical for all feasible values of vaccination effort (see §7.5.2)

Table 4. Summary of notable levels of the vaccination effort parameter, $\phi_{\langle model \rangle}$, for the different models. The first column contains 'fair comparison' values for the vaccination effort parameters of the various models, as calculated in §6.2. In our simulations, we allowed $\phi_{\langle model \rangle}$ to range between 0 and values generally above the 'fair comparison' values (except for ϕ_{inst}, for which we used the entire possible range of [0, 1]). The second column contains the minimal values of the vaccination effort parameter ($\phi_{\langle model \rangle}$) for which the individual equilibrium is to delay (that is, $\phi_{\langle model \rangle}$ at the end of the mortality plateau; see §7.2.1).

model	'fair comparison' value	value at end of mortality plateau
ϕ_{prev}	1582 per day	571 per day
ϕ_{susc}	0.1 per day	0.08 per day
ϕ_{inc}	5190 per day	1137 per day
ϕ_{inst}	—	0.82 per day
ϕ_{const}	0.1 per day	0.015 per day

— new cases (incidence), as in '200 new cases of smallpox were confirmed today'.

We consider separately how each of these types of information could affect smallpox vaccine uptake; in each case, we assume that the vaccination rate is proportional to the relevant quantity (e.g. prevalence). Note that, in standard epidemiological models [6], death rate is proportional to prevalence, so the first and second cases above are mathematically identical.

As a type of 'null model' for media-induced vaccination, we also consider the situation in which

— Vaccination rate is simply proportional to the size of the remaining susceptible population; this corresponds to a constant *per capita* vaccination rate for susceptible individuals (see the electronic supplementary material, appendix B.1). This can be regarded as a 'null model' to compare with models for the scenarios above in the following sense: individuals' proclivity to vaccinate is constant over time, and does not depend on the state of the epidemic (i.e. on prevalence or incidence, which are likely to be reported by the media), whereas the vaccination rate falls as the number of susceptibles decreases over time, meaning that fewer individuals per unit time are inclined to vaccinate.

We also consider two scenarios in which vaccine uptake is not influenced by the media, but is constrained by the capabilities of public health authorities:

— If an outbreak occurs, immediately vaccinate a proportion of the susceptible population. The proportion might describe the efficacy of a post-outbreak campaign in convincing those who have thus far avoided vaccination. Individuals who remain un-vaccinated after this post-outbreak campaign would be persons holding particularly radical anti-vaccine opinions.

— Susceptible individuals are vaccinated at a constant rate until there are no more susceptibles remaining.

Finally, for each of the above scenarios, we investigate the effect of a lag between the start of an outbreak and the initiation of the post-outbreak vaccination response (allowing for public health authorities to organize a response to the outbreak). Bauch *et al.* [4] assumed such a response lag in their model, which is otherwise identical to the final scenario described above.

The epidemic models associated with each of the above five scenarios are described in detail in §5.

3. Game-theoretical formulation

In this section, we adapt the game-theoretical framework of Bauch & Earn [5] to our current problem. We assume that all individuals have full knowledge and are rational (in the game-theoretical sense; see [11]).

We denote the proportion of the population vaccinated pre-emptively as p. Because a proportion r_v of those vaccinated will die, the pre-outbreak vaccine coverage (the proportion of the population that is immune prior to the outbreak) is $p_{eff} = p(1 - r_v)/(1 - pr_v)$ [4], which is slightly smaller than p. But, because none of the mathematical analysis and conclusions which follow are affected by this, and because the difference between p and p_{eff} is negligible, we refer to p as the pre-outbreak vaccine *coverage level* for simplicity (as in [4]).

Let $a \in [0, 1]$ be the probability of an outbreak ('a' for 'bioterrorist *attack* probability' or '*accidental* release probability') per lifetime (or whatever time period is under consideration). Consider two pure strategies: *vaccinate* and *delay*. The former vaccinates pre-emptively, before the beginning of an outbreak, and so receives (expected) pay-off $-r_v$; the latter delays vaccination until after an outbreak (at which point she/he may still be vaccinated during the public health post-outbreak vaccination campaign), and receives pay-off

$$- a[r_i \pi_p + \psi_p r_v], \qquad (3.1)$$

where π_p and ψ_p are the probabilities of a delayer being infected, or vaccinated, respectively, after an outbreak (the delayer

infection and vaccination probabilities are discussed in more detail in §5. A *mixed strategy* is specified by the probability P that an individual will choose to vaccinate pre-emptively. We also assume $r_v < ar_i$ because if it were not so, even if all delayers were infected in an outbreak, the risk of dying in an outbreak would be smaller than the risk of dying from the side-effects of the vaccine, hence there would be no reason to vaccinate.

The pay-off to an individual playing a mixed strategy (vaccinating with probability P) in a population in which the coverage level is p is given by

$$E(P, p) = -Pr_v - (1 - P)a(\pi_p r_i + \psi_p r_v). \qquad (3.2)$$

Equivalently, defining the *relative risk* of vaccination compared with infection as

$$r = \frac{r_v}{r_i}, \qquad (3.3)$$

we have $E(P, p) = -r_i[rP + (1 - P)a(\pi_p + \psi_p r)]$. Because the parameter r_i simply scales the game pay-off by a constant, it does not change the dynamics. We therefore use the rescaled pay-off function

$$E(P, p) = -[rP + (1 - P)a(\pi_p + \psi_p r)]. \qquad (3.4)$$

Suppose that a proportion ϵ of the population vaccinate with probability P and $1 - \epsilon$ vaccinate with probability Q. Following Bauch & Earn [5], we assume 100% vaccine efficacy, which implies coverage level $p = \epsilon P + (1 - \epsilon)Q$. (Note that in a homogeneous population where all individuals play the same strategy P, i.e. $\epsilon = 1$, the coverage is $p = P$.) The pay-offs to individuals playing P and Q in such a population are then

$$E_P(P, Q, \epsilon) = E(P, \epsilon P + (1 - \epsilon)Q) \qquad (3.5a)$$

or

$$E_Q(P, Q, \epsilon) = E(Q, \epsilon P + (1 - \epsilon)Q), \qquad (3.5b)$$

respectively, and the *pay-off gain* to an individual playing P rather than that to Q in this population is

$$\begin{aligned} \Delta E &= E_P(P, Q, \epsilon) - E_Q(P, Q, \epsilon) \\ &= -[rP + (1 - P)a(\pi_p + \psi_p r)] + [rQ + (1 - Q)a(\pi_p + \psi_p r)] \\ &= \left(\pi_p + r\psi_p - \frac{r}{a}\right)a(P - Q), \quad \text{where} \quad p = \epsilon P + (1 - \epsilon)Q. \end{aligned}$$

$$(3.6)$$

A strategy P^* is a *Nash equilibrium* (NE) if and only if (*iff*), in a population in which all individuals are playing P^*, no player employing a different strategy can achieve a higher pay-off. Mathematically, this means that for any other strategy $Q \in [0, 1]$ if the proportion playing Q is small enough (i.e. $1 - \epsilon$ is sufficiently small), then the pay-off gain to strategy P^* is non-negative, i.e. $\Delta E(P^*, Q, \epsilon) \geq 0$. When such an NE exists, we refer to this strategy as the *individual equilibrium* and denote it by p_i. This equilibrium is 'individual' in the sense that it is determined by individuals attempting to maximize their pay-offs (unlike the group optimum discussed in §4). Note, however, that this is a *population game* [5,12], so the pay-off to individuals depends on the frequencies of strategies in the entire population.

Additionally, consider a scenario whereby strategy P invades a population playing strategy Q. If, in this scenario, strategies P that are closer to the NE P^* than the prevalent strategy Q obtain a higher pay-off than the prevalent strategy, then P^* is called a *convergently stable Nash equilibrium* (CSNE). Mathematically, this is equivalent to demanding that

if $\epsilon \ll 1$, then

$$P^* < P < Q \leq 1 \Rightarrow \Delta E(P, Q, \epsilon) \geq 0$$

and

$$0 \leq Q < P < P^* \Rightarrow \Delta E(P, Q, \epsilon) \geq 0.$$

In order to proceed with the analysis, it is necessary to derive the probabilities π_p and ψ_p from an epidemiological model, either numerically or analytically (see the electronic supplementary material, appendix E). Proofs of existence and uniqueness of a CSNE are given for several cases in the electronic supplementary material, appendix G. These proofs depend on π_p being a decreasing function of p. We have shown this to be true when post-outbreak vaccination is instantaneous or proportional to incidence, and also when vaccination is proportional to prevalence and $\alpha\phi_{\text{prev}} > \gamma(1-\alpha)$. Based on biological intuition corroborated with simulations, we have assumed that π_p decreases with p for all the models considered here. This has also recently been proved for other post-outbreak vaccination models not considered here (F Bai, F Brauer 2015, personal communication).

4. Group optimum

From the perspective of a public health official (i.e. group interest), it is desirable to attain the vaccine coverage that minimizes mortality. From this group perspective, a strategy is specified by the proportion p of the population that is pre-emptively vaccinated. The currency with which we compare strategies is the *mortality cost* $C(p)$, i.e. the proportion of the population that is expected to die (either from smallpox infection or from vaccination),

$$C(p) = rp + (1 - p)a(\pi_p + \psi_p r), \qquad p \in [0, 1], \qquad (4.1)$$

where we have ignored a factor of r_i as in equation (3.4). The minimum mortality cost yields the *group optimum* coverage level, which we denote p_g. The minimum of $C(p)$ on $[0, 1]$ may be attained either at a local minimum in $(0, 1)$ or at one of the endpoints

$$C(0) = a(\pi_0 + \psi_0 r) \qquad (4.2a)$$

and

$$C(1) = r. \qquad (4.2b)$$

To completely specify the cost $C(p)$, we need the probabilities π_p and ψ_p, derived from the epidemiological model (see §5 and the electronic supplementary material, appendix E), just as for the individual equilibrium. We have found an exact analytical expression for p_g in one subcase (see the electronic supplementary material, appendix H) and calculated it numerically in the other cases.

5. Epidemiological models

In order to find the group optimum (p_g) and individual equilibrium (p_i), two key quantities are calculated from the epidemic models: the *delayer infection probability* π_p (the probability of a delayer being infected after an outbreak) and the *delayer vaccination probability* ψ_p (the probability that a delayer is eventually vaccinated, given an outbreak).

Both π_p and ψ_p depend on the disease dynamics and the post-outbreak vaccination scenario. In the following, we

assume that, in the absence of post-outbreak vaccination, the SIR model is adequate to represent the disease dynamics [13, §4]. The models do not include vital dynamics (births and deaths from all natural causes other than the disease), because the mean serial interval (also called the disease generation time, $t_{ser} = 22$ days [9, p. 141]) is much smaller than the mean lifetime (approx. 80 years in the USA [14]). Note that, for diseases for which the outbreak time scale is similar to the mean lifetime, vital dynamics can easily be included in the analysis (e.g. as in [5], where much longer term dynamics were considered).

Let $S(t)$, $I(t)$, $R(t)$ and $V(t)$ be the proportions of susceptible, infected, removed (recovered or dead from smallpox infection) and vaccinated individuals (immune or dead from vaccination), respectively, at time t. Our basic framework is the SIRV model, described by the differential equations

$$\dot{S} = -\beta SI - \dot{V}, \tag{5.1a}$$

$$\dot{I} = \beta SI - \gamma I, \tag{5.1b}$$

$$\dot{R} = \gamma I \tag{5.1c}$$

and

$$\dot{V} \geq 0, \tag{5.1d}$$

where $\dot{V}$ must be non-negative as indicated and is defined differently for each of the distinct scenarios of post-outbreak vaccination described in §2.

We assume that no one has natural immunity or retains immunity from vaccination decades earlier. This is an approximation, because many living individuals were vaccinated before smallpox was declared eradicated in 1979 [1], and many of those vaccinated individuals are probably still immune (vaccine-derived immunity seems to wane quite slowly and lifelong immunity is common [15]). However, smallpox is considered to have been eliminated in the USA as early as 1950, and while routine vaccination continued in some states well after that [1], the proportion of US residents younger than 60 who have been vaccinated is likely to be very small.

Thus, we assume that the coverage level prior to an outbreak is p, the proportion pre-emptively vaccinated. Consequently, prior to the outbreak, a proportion $1 - p$ of the population is susceptible. When a bioterrorist attack or accidental release takes place (at time $t = 0$), an *initial attack proportion* α of the susceptible population is infected. Thus,

$$S(0) = (1 - p)(1 - \alpha), \tag{5.2a}$$

$$I(0) = (1 - p)\alpha, \tag{5.2b}$$

$$R(0) = 0 \tag{5.2c}$$

and

$$V(0) = p. \tag{5.2d}$$

After an outbreak, the epidemic is over when no one remains infective ($I = 0$). In the electronic supplementary material, appendix C, we show rigorously that this is guaranteed to occur, either in finite time or in the limit as $t \to \infty$. In either case, we use the subscript ∞ to refer to the time at which the epidemic ends. Thus, S_∞, I_∞, R_∞ and V_∞ refer to the proportions of the population in the susceptible, infective, removed and vaccinated compartments at the end of the epidemic. With this notation, the probabilities of infection and vaccination for delayers are, respectively,

$$\pi_p = \frac{R_\infty - R(0)}{S_0 + I_0} = \frac{R_\infty}{1 - p} \tag{5.3a}$$

and

$$\psi_p = \frac{V_\infty - V_0}{S_0 + I_0} = \frac{V_\infty - p}{1 - p} = 1 - \frac{1 - V_\infty}{1 - p}$$
$$= 1 - \frac{S_\infty + I_\infty + R_\infty}{1 - p} = 1 - \pi_p - \frac{S_\infty}{1 - p}. \tag{5.3b}$$

We emphasize that R is the proportion of the population that has been infected (and consequently is either immune or has died); hence, $R(0) = 0$, because anyone who is immune at time $t = 0$ is immune from vaccination. Intuitively, there is no endemic equilibrium in these models, because the combination of vaccination and natural spread of disease must eventually cause susceptibles to be so rare that the disease cannot spread (recall that these models neglect vital dynamics).

Lastly, note that π_p is undefined at $p = 1$ (i.e. if everyone pre-emptively vaccinates), as there are no delayers for whom to calculate the probability of being infected. We define π_1 as the limit of the delayer infection probability,

$$\pi_1 = \lim_{p \to 1^-} \pi_p, \tag{5.4}$$

i.e. π_1 is the limit of π_p as pre-emptive vaccination approaches full coverage. In the electronic supplementary material, appendix D, we show that this limit is equal to the proportion of susceptibles initially infected in an outbreak, i.e. $\pi_1 = \alpha$ for all models considered.

In the following, we describe (and interpret mechanistically) various models that we compare, and present some analytical results. In all models, the vaccination rate depends on a vaccination effort parameter, $\phi_{\langle model \rangle}$, the exact interpretation of which is model dependent.

5.1. Vaccination rate ∝ disease prevalence

In this model, vaccination occurs at a rate proportional to disease prevalence (I). A plausible scenario to which such a model would apply is if people respond to media reports on disease prevalence. As a result of increasing disease prevalence, the public might perceive the risk of being infected as higher, and be moved to vaccinate. Consequently,

$$\dot{V} = \phi_{prev} \, \text{sgn}(S)I, \tag{5.5}$$

where

$$\text{sgn}(x) = \begin{cases} -1 & \text{if } x < 0, \\ 0 & \text{if } x = 0, \\ 1 & \text{if } x > 0. \end{cases}$$

This model could also represent the case where vaccination rate is proportional to death rate, i.e. people vaccinate in response to media reports on new disease-induced deaths. Because the death rate is proportional to the rate at which the removed compartment, R, grows, which is proportional to I, the vaccination rate would also be proportional to I.

In the electronic supplementary material, appendix E.1.1, we find the final size relations [16–18] for the model defined by equation (5.5). These are given by

$$S_\infty = \begin{cases} 0 & \text{if } p < p_0 \text{ or } 1 \leq p_m, \\ S_\infty^1 & \text{if } p_0 \leq p \leq 1, \end{cases} \tag{5.6}$$

$$R_\infty = \begin{cases} 1 - p - \dfrac{\phi_{prev}}{\beta} \ln\left(\dfrac{\beta}{\phi_{prev}} S(0) + 1\right) & \text{if } p < p_0 \text{ or } 1 \leq p_m, \\ \dfrac{\gamma}{\gamma + \phi_{prev}} (1 - p - S_\infty^1) & \text{if } p_0 \leq p \leq 1 \end{cases}$$
$$\tag{5.7}$$

and

$$
V_\infty = \begin{cases} p + \dfrac{\phi_{\text{prev}}}{\beta}\ln\left(\dfrac{\beta}{\phi_{\text{prev}}}S(0) + 1\right) & \text{if } p < p_0 \text{ or } 1 \le p_m, \\[2ex] \dfrac{1}{\gamma + \phi_{\text{prev}}}(\phi_{\text{prev}}(1 - S_\infty^1) + \gamma p) & \text{if } p_0 \le p \le 1, \end{cases}
$$

(5.8)

with

$$
S_\infty^1 = -\frac{1}{\beta}\left(\phi_{\text{prev}} + (\gamma + \phi_{\text{prev}})\right.
$$
$$
\left. \times\, W_0\left(-\frac{\beta S(0) + \phi_{\text{prev}}}{\gamma + \phi_{\text{prev}}}e^{\frac{-\beta(1-p)+\phi_{\text{prev}}}{\gamma+\phi_{\text{prev}}}}\right)\right),
$$

(5.9)

$$
p_m = 1 + \frac{\alpha\phi_{\text{prev}} - \gamma(1 - \alpha)}{\beta(1 - \alpha)}
$$

(5.10)

and

$$
p_0 = 1 + \frac{\phi_{\text{prev}}}{\beta(1 - \alpha)} + \frac{\gamma + \phi_{\text{prev}}}{\beta}
$$
$$
\times\, W_k\left(-\frac{\phi_{\text{prev}}}{(1-\alpha)(\gamma + \phi_{\text{prev}})}e^{-\frac{\phi_{\text{prev}}}{(1-\alpha)(\gamma+\phi_{\text{prev}})}}\right),
$$

(5.11)

where $k = 0$ if $p_m < 1$ and $k = -1$ if $p_m \ge 1$. W_0 is the principal branch of Lambert's W function [19,20], and W_{-1} is its other real branch (see the electronic supplementary material, appendix A). p_m is the unique maximum of the function S_∞^1. S_∞^1 has two roots, one at $p = 1$, and the other at p_0, which need not lie in the interval $[0, 1]$ (p_0 is a formal root and need not correspond to a meaningful probability). Note that if $p_m > 1$ then $p_0 > p_m$, and if $p_m < 1$ then $p_0 < p_m$.

If $p_m > 1$, then no delayers will remain susceptible at the end of the epidemic (i.e. all delayers will be either vaccinated or infected), regardless of the initial vaccine coverage level p. Moreover, if $p_m < 1$, but $p_0 < 0$, there are always some delayers who remain susceptible at the end of the epidemic, regardless of the initial coverage level p. If $0 < p_0 < p_m < 1$, then for $p \in [0, p_0]$ there will be no susceptibles left at the end of the epidemic, and for $p \in (p_0, 1)$ there will be some remaining susceptibles. Thus, there is a wide range of parameter values for which some susceptibles remain at the end of the epidemic; in such cases, $\pi_p + \psi_p < 1$. Numerical evidence and biological intuition suggest that π_p is a decreasing function of p, and we assume that this is the case from here on (this is proven for $p_m \ge 1$ in the electronic supplementary material, appendix E.1.3).

Finally, because the mean infectious period (7 days; see table 2 and §6.1) is longer than the time required to complete the vaccination programme (possibly as short as 3 days [21]), it is interesting to take the limit $\gamma \to 0$ (corresponding to an infinite infectious period) while keeping $\mathcal{R}_0 = \beta/\gamma$ fixed. In this limit, $p_m \to \infty$ so $S_\infty = 0$ (equation (5.6)), which is in accordance with the assumption—made in [4]—that individuals are ultimately either removed or vaccinated.

We show in the electronic supplementary material, appendix G.1, that there is always a unique CSNE, that is, a 'best strategy' from the individual perspective. Moreover, an analytical expression for this individual equilibrium can be found if

either $\quad \phi_{\text{prev}} \ge \gamma(1 - \alpha)/\alpha$ (5.12a)

or $\quad 0 \le p_0 < p_m \le 1, \quad \pi_0 > \rho_1 > \pi_{p_0} \quad \text{and} \quad \pi_{p_0} < \rho_2$. (5.12b)

In addition, we find an analytical formula for the group optimum when $\phi_{\text{prev}} \ge \gamma \, (1 - \alpha)/\alpha$ (see the electronic supplementary material, appendix H, for details).

5.2. Vaccination rate $\propto$ incidence

A vaccination rate proportional to incidence again reflects media-induced vaccination. However, in this model, the public reacts to reports of new cases, rather than reports of the total number of sick individuals. Thus,

$$\dot{V} = \phi_{\text{inc}}SI. \tag{5.13}$$

In the electronic supplementary material, appendix E.2, we show that

$$S_\infty = -\frac{\gamma}{\beta}W_0\left(-\frac{\beta(1-p)(1-\alpha)}{\gamma}e^{-\frac{\beta+\phi_{\text{inc}}\alpha}{\gamma}(1-p)}\right), \tag{5.14}$$

$$V_\infty = p + \frac{\phi_{\text{inc}}}{\beta + \phi_{\text{inc}}}((1-p)(1-\alpha) - S_\infty) \tag{5.15}$$

and $\quad R_\infty = 1 - p - \dfrac{\phi_{\text{inc}}(1-p)(1-\alpha) + \beta S_\infty}{\beta + \phi_{\text{inc}}}.$ (5.16)

Again, because there are susceptible individuals left at the end of the epidemic, $\pi_p \ne 1 - \psi_p$. We show that $\partial_p \pi_p < 0$ (in the electronic supplementary material, appendix E.2) and find that there is a unique CSNE, p_i, for which an exact formula is derived in the electronic supplementary material, appendix G.2.

5.3. Vaccination rate $\propto$ proportion still susceptible

In this scenario, susceptible individuals vaccinate at a rate

$$\dot{V} = \phi_{\text{susc}}S. \tag{5.17}$$

This is a null model, in the sense that susceptible individuals have a constant probability per unit time of being vaccinated, ϕ_{susc}, independent of the state of the outbreak, as shown in the electronic supplementary material, appendix B.1.

We were able to obtain analytical final size relations for this model (see the electronic supplementary material, appendix E.3), but we found the formulae too cumbersome to be useful. Thus, the remainder of our analysis of this model was performed by integrating the differential equations numerically. In our numerical simulations, we always find that π_p decreases with p (in the electronic supplementary material, appendix G.3, our proof of the existence of a CSNE depends on this being true).

5.4. Instantaneous vaccination of a proportion ϕ_{inst} of the population

Some experts believe that the entire USA could be vaccinated in 3 days [21], which is less than the latent period of smallpox. Consequently, instantaneous vaccination of a proportion ϕ_{inst} of the population remaining susceptible after the outbreak is also a realistic scenario to model. In this case, once vaccination has occurred, the disease simply spreads according to the standard SIR model,

$$\dot{S} = -\beta SI, \tag{5.18a}$$

$$\dot{I} = (\beta S - \gamma)I \tag{5.18b}$$

and $\quad \dot{R} = \gamma I,$ (5.18c)

with initial conditions given by

$$S(0) = (1 - p)(1 - \alpha)(1 - \phi_{\text{inst}}),$$
$$I(0) = (1 - p)\alpha,$$
$$R(0) = 0,$$
$$V(0) = p + \phi_{\text{inst}}(1 - p)(1 - \alpha).$$

Note that in this scenario we deviate from the convention we use for all the other models, in which $S(0)$ is the initial density of susceptibles prior to the beginning of the post-outbreak vaccination response. Here, $S(0)$ is the density of susceptibles *after* the post-outbreak vaccination response has taken place.

For this scenario, we find (in the electronic supplementary material, appendix E.4)

$$S_\infty = -\frac{\gamma}{\beta} W_0 \left(-\frac{\beta}{\gamma} S(0) e^{-\frac{\beta}{\gamma}(1 - V(0))} \right) \qquad (5.19)$$

and

$$R_\infty = \frac{\gamma}{\beta} \ln \frac{S(0)}{S_\infty}. \qquad (5.20)$$

We also show that π_p is a decreasing function of p, ψ_p is constant and $\pi_p + \psi_p \neq 1$ (see the electronic supplementary material, appendix E.4). In addition, we have proved that, for this model, there is always a unique CSNE, for which we derive an exact formula in the electronic supplementary material, appendix G.4.

5.5. Constant rate vaccination

This is the model of Bauch *et al.* [4], in which vaccination occurs at a constant rate ϕ_{const}. Note that in [4] vaccination begins after a response lag t_{lag}, which is the public health services' response time. This lag is taken to be $t_{lag} = 0$ except in §7.5.

For consistency with [4], we included an exposed (but not infective) stage (E), in this model, making it an SEIRV model. This contrasts all the other scenarios, which we have modelled using a simpler SIRV formulation. Our choice of the SIRV framework for the new scenarios is motivated by mathematical tractability and by work subsequent to [4], indicating that SEIR dynamics are captured by an appropriately parametrized SIR model (see §6.1, but see §7.5.1 for an exception).

The model equations for the constant rate vaccination scenario are

$$\dot{S} = -\beta SI - \dot{V}, \qquad (5.21a)$$

$$\dot{E} = \beta SI - \sigma E, \qquad (5.21b)$$

$$\dot{I} = \sigma E - \gamma I, \qquad (5.21c)$$

$$\dot{R} = \gamma I \qquad (5.21d)$$

and $\quad \dot{V} = \begin{cases} \phi_{const} & \text{if } t_{lag} < t \text{ and } S > 0, \\ 0 & \text{if } t \leq t_{lag} \text{ or } S \leq 0. \end{cases} \qquad (5.21e)$

We have not found a final size relation for this model.

Under the biologically plausible assumption that π_p decreases with p (verified by simulation), Bauch *et al.* [4] have shown the existence of a unique CSNE for this model.

6. Parameter estimates, fair comparisons of models and numerical procedures

Because one of the models we investigate includes an exposed class, and the vaccination effort parameter $\phi_{\langle model \rangle}$ has a different meaning in each scenario we examine, fair comparisons of model results are not completely straightforward. In this section, we consider how the various models can be compared.

6.1. SIR versus SEIR

It is well known that similar dynamics are obtained with the standard SIR and SEIR models with identical basic reproductive number, $\mathcal{R}_0$, if the mean infectious period in the SIR

model is set equal to the sum of the mean latent and infectious periods in the SEIR model [6, p. 668]. More generally, models can be fairly compared if they have the same mean serial interval [13, §4].

Estimates of the basic reproductive ratio $\mathcal{R}_0$ of smallpox vary in the range $3 \leq \mathcal{R}_0 \leq 10$ [6–8]. Following [4], we take $\mathcal{R}_0 = 5$. We take the mean serial interval to be $t_{ser} = 22$ days, as in [9, p. 141] (but note that [4] used $t_{ser} = 14$ days, and [22] estimated $t_{ser} = 17.7$ days).

In the constant rate vaccination model, we take the mean latent period to be $1/\sigma = 15$ days [9, p. 141] (based on summing the incubation and prodrom periods, which typically last 12 and 3 days, respectively; see [1, p. 188]). In an SEIR model, the mean serial interval is the sum of the mean latent and infectious periods [13,23]; hence, $1/\gamma = 22 - 15 = 7$ days and $\beta = \gamma \mathcal{R}_0 = 5/7$ per day. In the SIRV models, we take $1/\gamma = t_{ser}$, whereas β is modified so that $\mathcal{R}_0 = 5$ (i.e. $\beta = \gamma \mathcal{R}_0 = 5/22$ per day).

6.2. Vaccination effort parameter $\phi_{\langle model \rangle}$

Public health policy changes will affect the vaccination effort parameter $\phi_{\langle model \rangle}$, where $\langle model \rangle$ refers to any of 'prev', 'inc', 'susc', 'inst' or 'const'. In order to compare the outcomes of the various vaccination scenarios, for each vaccination model, we find the *fair comparison value* of $\phi_{\langle model \rangle}$, that is, the value of $\phi_{\langle model \rangle}$ that yields a maximal vaccination rate that is equal to the fixed rate in the constant rate vaccination model of Bauch *et al.* [4], $\dot{V} = 0.1$ per day (see description under ϕ_{const} below). This allows us to identify, for each scenario, ranges of $\phi_{\langle model \rangle}$ that can feasibly be attained in reality (i.e. $\phi_{\langle model \rangle}$ between 0 and the fair comparison value). Our aim is then to compare the different vaccination strategies in terms of vaccine doses used and total expected mortality (we will be interested in the values of these observables at both the individual equilibrium and the group optimum). The fair comparison values are summarized in table 4.

ϕ_{prev}. In the prevalence model, $\dot{V} = \phi_{prev} I$, the vaccination rate is proportional to the prevalence, I, and the vaccination effort parameter ϕ_{prev} is the rate of vaccination *per infected individual*. In the electronic supplementary material, appendix F.1, we calculate the maximal vaccination rate as a function of the model parameters, α, β, γ and ϕ_{prev} and p. We find that the maximal vaccination rate for a given initial coverage, p, decreases with the vaccination effort, ϕ_{prev}. We also find that, when α, β and γ are as in tables 1 and 2, a maximal vaccination rate of 0.1 per day is obtained when $\phi_{prev} \approx 1582$ per day.

ϕ_{inc}. In the incidence model, $\dot{V} = \phi_{inc} SI$, the vaccination effort parameter ϕ_{inc} is the vaccination rate *per infective per susceptible*. In the electronic supplementary material, appendix F.2, we calculate the maximal vaccination rate, as a function of the model parameters, α, β, γ and ϕ_{inc}. We show that the maximal vaccination rate, $\max\{\dot{V} : t \geq 0, p \in [0, 1]\}$, is an increasing function of ϕ_{inc}, and that in order to obtain a maximal vaccination rate of 0.1 per day or lower, with α, β and γ as in tables 1 and 2, one needs $\phi_{inc} \approx 5190$ per day.

ϕ_{susc}. With $\dot{V} = \phi_{susc} S$, the vaccination effort parameter ϕ_{susc} is the vaccination rate *per susceptible individual* (alternatively, ϕ_{susc} can be interpreted as the probability per unit time of a delayer being vaccinated; see the electronic supplementary material, appendix B.1). In this model, the vaccination

rate $\dot{V}$ is always decreasing, because S can only decrease, so $\max\{\dot{V}\} = \phi_{\text{susc}}S(0) = \phi_{\text{susc}}(1 - \alpha)(1 - p)$ (cf. equation (5.2a)). Because the maximal vaccination rate decreases with increasing initial coverage, p, the maximal vaccination rate is attained with no pre-emptive vaccination ($p = 0$). Because $S(0) = 1 - \alpha$, the maximal vaccination rate is $\max\{\dot{V}\} = (1 - \alpha)\phi_{\text{susc}}$, and a vaccination rate of 0.1 per day is attained for $\phi_{\text{susc}} = 0.1/(1 - \alpha) \approx 0.1$ per day (because $\alpha \ll 1$).

ϕ_{inst}. For instantaneous vaccination, the vaccination effort parameter ϕ_{inst} is the proportion of susceptibles instantaneously vaccinated when an outbreak occurs. Thus, $\phi_{\text{inst}} \in [0, 1]$. The vaccination rate is either 0 (if $\phi_{\text{inst}} = 0$) or effectively infinite (if $0 < \phi_{\text{inst}} \leq 1$, because vaccination occurs all at once). We thus consider the entire range $0 \leq \phi_{\text{inst}} \leq 1$, because there is no value of ϕ_{inst} that results in a vaccination rate of 0.1 per day.

ϕ_{const}. With $\dot{V} = \phi_{\text{const}}$, the vaccination rate is constant, so ϕ_{const} is simply the proportion of the total population that can be vaccinated per unit time. Bauch *et al.* [4] estimated ϕ_{const} for New York City to be

$$\phi_{\text{const}} = (5000 \text{ vaccinators}) \times \left(\frac{200 \text{ people per day}}{\text{vaccinator}}\right)$$

$$\times \frac{1}{10^7 \text{ people}} = \frac{0.1}{\text{day}}. \tag{6.1}$$

A rate of $\phi_{\text{const}} = 0.1$ per day means the entire population can be vaccinated in 10 days.

6.3. Numerical procedures

When generating figures 1–4, calculations of the following quantities were necessary: the mortality cost, $C(p)$ (equation (4.1)), the group optimum, p_{g} (§4), and the individual equilibrium, p_{i} (§3).

To find p_{g}, $C(p)$ was numerically minimized using the `optimize` function in R [24]. p_{i} was found by implementing the procedures described in the electronic supplementary material, appendix G, for the various models, using R's `uniroot` function.

The calculations of both p_{g} and p_{i} depend on π_p and ψ_p, the probabilities of a delayer being infected or vaccinated, respectively (equation (5.3)). For the models in which the vaccination rate is proportional to prevalence or incidence, we used the final size relations reported in §§5.1 and 5.2, respectively, to calculate π_p and ψ_p. For the remaining models, π_p and ψ_p were obtained by numerically integrating the differential equations using the `deSolve` package [25] in R [24].

When generating figure 5, for *all* the models π_p and ψ_p were calculated by numerical integration of the differential equations.

7. Results and discussion

7.1. Group optimum versus individual equilibrium

Figure 1 shows the group optimum p_{g} (red) and individual equilibrium p_{i} (black), as the vaccination effort parameter $\phi_{\langle\text{model}\rangle}$ is varied, for the different models. As expected, the group-optimal coverage is never smaller than the individual equilibrium, and both decrease as $\phi_{\langle\text{model}\rangle}$ is increased. The difference, $p_{\text{i}} - p_{\text{g}}$, tends to grow initially with $\phi_{\langle\text{model}\rangle}$, but eventually decreases to 0, because the coverage at both the group optimum and individual equilibrium always drops to 0 if the vaccination rate parameter $\phi_{\langle\text{model}\rangle}$ is increased sufficiently. It is also evident that the difference between the group-optimal coverage and the individual equilibrium depends strongly on the vaccination model used. In general, this difference is much smaller for the instantaneous and constant rate vaccination models than it is for the other models in which vaccination is affected by the state of the outbreak.

7.2. Mortality cost versus vaccination cost

Figure 2 shows the mortality cost (proportion of the population that dies; figure 2a) and the vaccination cost (proportion of the population that is vaccinated by the end of the outbreak; figure 2b) as functions of the vaccination effort parameter, $\phi_{\langle\text{model}\rangle}$, for the various post-outbreak response scenarios.

7.2.1. Mortality plateau

The most striking feature of figure 2 is the plateau in mortality cost at the individual equilibrium for low values of $\phi_{\langle\text{model}\rangle}$. This plateau can be explained using the Bishop–Cannings theorem [12,26], which implies that if the individual equilibrium is a mixed strategy then the pay-off for vaccinating and delaying must be the same. For low values of $\phi_{\langle\text{model}\rangle}$, the individual equilibrium is mixed ($0 < p_{\text{i}} < 1$), so the mortality cost associated with vaccinating is the same as for delaying, which is therefore the same as the overall mortality cost. Because the mortality cost for vaccinating is equal to the risk from vaccination (r_{v}, or r in normalized units; cf. equation (3.3) and tables 1 and 2), the overall mortality cost is constant at r_{v} (or r in normalized units) as long as the individual equilibrium is mixed. As $\phi_{\langle\text{model}\rangle}$ is increased, the individual equilibrium p_{i} is decreased (see §7.1). When p_{i} reaches 0, there is a pure strategy equilibrium (i.e. always delay), so the Bishop–Cannings theorem no longer applies; then, the overall mortality is the mortality of delayers, which is $-a[r_i\pi_p + \psi_p r_{\text{v}}]$ (see equation (3.1)) and this decreases as $\phi_{\langle\text{model}\rangle}$ is increased (because the epidemic is extinguished faster).

7.2.2. Public health strategy implications of the mortality plateau

There is an important implication of the plateau in mortality that occurs for small $\phi_{\langle\text{model}\rangle}$ if vaccination is voluntary: in order to achieve *any* reduction in overall mortality, the post-outbreak vaccination response must be so strong that no individual would choose to vaccinate pre-emptively ($p_{\text{i}} = 0$, i.e. the equilibrium is for everyone to delay). Only if the post-outbreak vaccination response is already sufficiently efficient ($\phi_{\langle\text{model}\rangle}$ is already sufficiently large; figure 1) can outbreak size (and hence overall mortality) be reduced by further enhancing the post-outbreak vaccination response (i.e. by increasing $\phi_{\langle\text{model}\rangle}$).

Note that, for every model examined here, the right-hand (high effort) edge of the mortality plateau in figure 1 occurs for a value of vaccination effort $\phi_{\langle\text{model}\rangle}$ lower than the fair comparison value (table 4). Thus, at the fair comparison values of $\phi_{\langle\text{model}\rangle}$, the individual equilibrium is always to delay vaccination, and mortality can be reduced by increasing vaccination effort, $\phi_{\langle\text{model}\rangle}$.

However, in §7.5, we show that any lag between the start of an outbreak and the beginning of post-outbreak vaccination extends the mortality plateau to higher vaccination efforts, $\phi_{\langle\text{model}\rangle}$, and a long enough lag makes reducing mortality by increasing vaccination effort impossible. We discuss the implications of this for public health strategies further in §7.5.

Figure 1. Variation of the group optimum p_g (red) and the individual equilibrium p_i (black) with $\phi_{\langle\text{model}\rangle}$ (each panel presents results for a different vaccination model). Note the different ranges of $\phi_{\langle\text{model}\rangle}$ (on the abscissa) for different models. (Online version in colour.)

7.2.3. Generality of the mortality plateau

It is important to note that the mortality plateau described earlier is a general phenomenon that applies not only to the post-outbreak vaccination scenarios examined here, but also to any reasonable post-outbreak vaccination scenario. More precisely, suppose public health agencies have some measure of control over a vaccination effort parameter, ϕ. Suppose also that $\phi = 0$ corresponds to no possibility of obtaining vaccine post-outbreak, and that the probabilities of a delayer being infected or vaccinated after an outbreak (π_p and ψ_p, respectively) are continuous functions of p and ϕ (for $0 \leq p < 1$ and $\phi \geq 0$). As in §3, the costs for delaying and vaccinating individuals are then $a(r_i\pi_p + r_v\psi_p)$ and r_v, respectively. Now suppose the following additionally:

(1) If there is no possibility of being vaccinated post-outbreak ($\phi = 0$), and no one is vaccinated pre-emptively ($p = 0$),

then individuals are at greater risk than if they had been vaccinated pre-emptively (i.e. $a(r_i\pi_p + r_v\psi_p)|_{p=0,\phi=0} > r_v$).

(2) As the initial coverage approaches 100% ($p \to 1$), the disease does not spread any further than the initial infected cohort ($\pi_p \to \alpha$). Note that, as shown in the electronic supplementary material, appendix D, this assumption holds for all of the models considered in this paper, and the mathematical argument used to show this is quite general.

(3) The risk that a delayer is infected in the initial infection event and then dies is smaller than the risk of mortality from the vaccine alone ($\alpha r_i < r_v$).

The vaccination game with this post-outbreak vaccination scenario is a population game, and thus must have at least one Nash equilibrium [27, theorem 2.1.1, p. 24].

So for, low enough vaccination effort ϕ, if coverage p is low, it is more costly to delay than to vaccinate (from the

Figure 2. Variation of the mortality cost (proportion of the population that dies) and vaccine dose cost (proportion of the population that is vaccinated by the end of the outbreak) as functions of the vaccination effort parameter $\phi_{\langle model \rangle}$, for different vaccination models. Each row depicts the mortality costs (panel a) and vaccine dose costs (panel b), at the group optimum (red) and individual equilibrium (black) for one model. Note the different ranges of $\phi_{\langle model \rangle}$ for different models. (Online version in colour.)

first assumption above). Conversely, if coverage p is high enough, the third assumption above implies that delaying is preferable to vaccinating pre-emptively. It follows that any individual equilibrium that results from the vaccination game is a mixed NE ($0 < p_i < 1$). The preceding argument presented in §7.2.1 (using the Bishop–Cannings theorem) now implies the existence of a plateau in mortality.

7.2.4. Vaccination cost plateau

Figure 2b also show a plateau for sufficiently *large* vaccination efforts (except for the constant rate vaccination model). Unlike the mortality plateau, this vaccination cost plateau is not rigorously a constant (it changes very slightly as a function of $\phi_{\langle model \rangle}$), but it is certainly a plateau for all intents and purposes. This plateau occurs because overall

vaccination rises with the vaccination effort, $\phi_{\langle model \rangle}$, and cannot exceed $V_\infty = 1$, so vaccination costs must eventually taper off.

7.2.5. Perceived versus real risks

The general public is likely to overestimate vaccine-induced mortality [28–30], which would tend to decrease the pre-outbreak vaccine coverage under voluntary vaccination. The game-theoretical framework we employ assumes individuals behave rationally and possess perfect information on which to base their decisions, but it is possible to relax the assumption of perfect information while maintaining that of rationality. Thus, to account for misinformation regarding the dangers of vaccination (possibly as a result of vaccine scares), we can interpret r_i and r_v as the *perceived* risks of infection and vaccination (rather than the actual risks) to predict the effective level of vaccine coverage prior to an

Figure 3. Variation of relative difference in mortality and vaccine dose costs with $\phi_{\langle model \rangle}$, for different vaccination models. Each row depicts the relative mortality cost difference (panel *a*) and relative vaccine dose cost difference (panel *b*) for one model. Note the different ranges of $\phi_{\langle model \rangle}$ for different models.

outbreak (note that perceived risks are to be used to predict the individual equilibrium, p_i, but not when predicting the group optimum p_g, nor when predicting the mortality and vaccination costs at *either* of these coverages). Consequently, public health agencies can potentially reduce mortality by attempting to influence the public's estimate of r (the risk of vaccination relative to infection). For example, risk perception might be influenced by a media campaign aiming to increase the accuracy of the public's perception of vaccine safety and promote pre-emptive vaccination.

7.3. Comparison of relative costs
In figure 3a, we look at the relative mortality cost difference, that is, in units of the cost of optimal mandatory vaccination. Explicitly, we examine how $(C(p_i) - C(p_g))/C(p_g)$ varies with $\phi_{\langle model \rangle}$ for each model. Similarly, we plot the relative difference in vaccination $(V_\infty(p_i) - V_\infty(p_g))/V_\infty(p_g)$ (figure 3b), which is the relative vaccine dose cost difference between voluntary and mandatory vaccination.

7.3.1. Large variation in relative mortality cost
Observe that, in figure 3a, the relative mortality cost difference is always non-negative (as expected from the definition of the group optimum as the pre-outbreak coverage for which expected mortality cost is minimal). There is substantial variability among the models in the dependence of the relative mortality cost differences on the vaccination parameter $\phi_{\langle model \rangle}$. In particular, if vaccination rate is proportional to incidence or prevalence, variation in relative mortality cost is an order of magnitude smaller than if vaccination is instantaneous or at a constant rate. The vaccination scenario that exhibits the largest variation in relative mortality costs is instantaneous vaccination. In this scenario, a voluntary vaccination policy could result in over 150% more deaths than if vaccination were mandatory.

7.3.2. Modest variation in relative vaccine dose cost
There is also substantial variability in the pattern of variation of relative vaccine dose cost as a function of $\phi_{\langle model \rangle}$ among the

different models (figure 3b). However, for all the models, variation in relative vaccine dose cost as a function of $\phi_{\text{(model)}}$ is much less than the corresponding variation in relative mortality cost. The maximum variation in relative vaccine dose cost reaches approximately 16% for the models in which vaccination is proportional to prevalence or incidence. This relatively large variation can be attributed to low pre-outbreak vaccination coverage (at the individual equilibrium) causing high disease prevalence and incidence; consequently, because vaccination rate is proportional to prevalence or incidence, there is correspondingly high post-outbreak vaccination, which overshoots that which would be required to minimize group mortality. In these two situations, the vaccine dose cost at the individual equilibrium can be greater than at the group optimum. In any case, the relatively small difference in overall vaccine dose costs, both as a function of vaccination effort ($\phi_{\text{(model)}}$) and among vaccination scenarios (see figure 2b), suggests that vaccine dose cost should probably not be a factor in public health policy decisions.

7.4. Vaccine dose cost as a function of mortality cost

Figures 2 and 3 present mortality costs and vaccine dose costs as functions of vaccination effort for the various models. Because the meaning of the vaccination effort parameter $\phi_{\text{(model)}}$ differs among models, it is not straightforward to make meaningful comparisons among the various models (which is why we calculated 'fair comparison' values in §6). In this section, we display results for the various models, factoring out the vaccination effort parameter. For each model, figure 4 shows the vaccine dose cost *as a function of* mortality cost. In health economics terms, this can be considered a *cost-effectiveness analysis* [31].

In figure 4, the squares indicate the point in the mortality-cost–vaccination-cost plane where the vaccination effort ($\phi_{\text{(model)}}$) is the lowest that we considered. Increasing vaccination effort (while remaining at the individual equilibrium or the group optimum) corresponds to moving away from the square along the plotted curves.

The graphs in figure 4 allow us to answer practical questions such as 'If we want to ensure that no more than one in every 10 million citizens dies, how many vaccine doses are required in each scenario?' or 'If we have a stockpile of vaccine doses sufficient for 30% of the population, what percentage of the population can be expected to die if there is an outbreak in each scenario?' Of course, by construction the graphs do not indicate how much effort ($\phi_{\text{(model)}}$) is required to achieve the desired results. We emphasize that—as shown in the previous section—vaccine dose cost at the individual equilibrium or group optimum hardly varies as a function of vaccination effort ($\phi_{\text{(model)}}$), so the 'practical' questions are not necessarily well posed (e.g. if we have sufficient vaccine doses for only 30% of the population, then neither the individual equilibrium nor the group optimum can ever be achieved). This is true for all the models *with parameters appropriate for smallpox*; for another disease graphs like figure 4 could have genuine practical value for public health policy analysis (e.g. setting $\mathcal{R}_0 = 1.25$ and keeping all other model parameters as in tables 1 and 2 causes the vaccine cost to vary between 25% and 99.999%).

In figure 4, when the vaccination rate is proportional to either prevalence or incidence, note that, as the vaccination effort, $\phi_{\text{(model)}}$, increases, two phases of behaviour are apparent for the costs at both p_i and p_g: first, vaccine dose cost

rises but no change in mortality cost is observed (this is caused by the plateau in mortality described in §7.2.1). Then, for all but the instantaneous vaccination model, vaccine dose cost remains virtually constant (note the differences in the scales of the vertical axes among the various panels), but mortality costs decrease.

It is interesting to note that the dependence of vaccine costs on mortality costs at the group optimum varies among the models. For example, when vaccination is proportional to remaining susceptibles, and for the constant rate vaccination model, we see in figure 4 that at the group optimum, as mortality cost is decreased, vaccine dose cost decreases at first, but then increases. Thus, in these situations, one can lower both the mortality and the vaccine dose cost at the same time by increasing vaccination effort (in health economics terms, the decision to use higher vaccination effort has negative marginal cost in vaccine doses per life saved). This contrasts the models in which vaccination is instantaneous, or proportional to incidence or prevalence, in which we observe that, as mortality cost is decreased, the vaccine dose cost at the group optimum remains constant and then increases sharply.

Finally, for the instantaneous vaccination model, there is a range of vaccination efforts for which one can reduce mortality without increasing vaccine dose costs at the group optimum. In this parameter range, the increase in vaccine dose cost necessary to decrease mortality at the individual equilibrium is small at first, but grows larger as mortality is decreased.

7.5. Effect of vaccination response lag t_{lag}

We have implicitly assumed that in any of the scenarios we have considered the vaccination response will begin as soon as an outbreak is seeded by a bioterrorist attack or accidental release. In contrast, Bauch *et al.* [4] assumed a lag of two weeks between the seeding of an outbreak and the initiation of a vaccination response. In this section, we investigate the effect of a *response lag* of t_{lag} days between an outbreak being seeded and the post-outbreak vaccination campaign beginning (so far, we have assumed $t_{\text{lag}} = 0$ days; in [4], $t_{\text{lag}} = 14$ days was assumed).

Intuitively, adding a lag between the beginning of an outbreak and the vaccination response allows the disease to spread unhindered for some time, which increases the probability of delayers being infected, thus decreasing the pay-off for delaying. As a result, the individual equilibrium p_i increases, which consequently extends the mortality plateau (§7.2.1) to higher values of $\phi_{\text{(model)}}$.

7.5.1. The critical lag, t_{lag}^*

For a disease such as smallpox with $\mathcal{R}_0 \sim 5$, the expected final size of an uncontrolled epidemic is greater than 99.9% of the population. If no one is pre-emptively vaccinated, and the response lag after an outbreak is seeded is sufficiently long, almost everyone will have been infected before the response begins, i.e. if t_{lag} is sufficiently long then delayers will almost certainly be infected before they can be vaccinated. Consequently, unless the probability of an outbreak (a) is negligible, delaying will be riskier than vaccinating pre-emptively, so the individual equilibrium will not be for everyone to delay: we will certainly have $p_i > 0$. It follows that for response lags longer than some *critical lag*, t_{lag}^*, mortality cannot be reduced no matter how much effort is applied in the post-outbreak vaccination response

Figure 4. Vaccine dose cost *as a function of* mortality cost at the group optimum, p_g (red), and the individual equilibrium, p_i (black), for the different models. Squares represent values at lowest $\phi_{\langle\text{model}\rangle}$ simulated. (Online version in colour.)

(i.e. the mortality plateau described in §7.2.1 continues for arbitrarily large values of $\phi_{\langle\text{model}\rangle}$).

A more precise argument allows us to estimate t^*_{lag}. Suppose the initial coverage is $p = 0$ (no pre-emptive vaccination). If the risk of becoming infected and dying is larger than the risk from vaccinating, i.e. $ar_i\pi_0 > r_v$ (or, equivalently, $\pi_0 > r/a$), then delaying will not be the individual equilibrium. For any vaccination scenario, the delayers' probability of being infected by the end of the outbreak (equation (5.3a)) is greater than or equal to their probability of being infected before the vaccination response begins (at time t_{lag}),

$$\pi_0 \geq \left(I(t_{\text{lag}}) + R(t_{\text{lag}}) \right)\Big|_{p=0}. \tag{7.1}$$

Therefore, if

$$\left(I(t_{\text{lag}}) + R(t_{\text{lag}}) \right)\Big|_{p=0} > \frac{r}{a}, \tag{7.2}$$

then $\pi_0 > r/a$ and delaying is guaranteed not to be the individual equilibrium. But for *any* post-outbreak vaccination scenario that includes a response lag, when $t < t_{\text{lag}}$ the removed proportion of the population, $R(t)$, follows the standard SIR model solution (with no vaccination). For the SIR model with

no vaccination ($p = 0$; a, α and $\mathcal{R}_0$ as in table 1), numerical simulation shows that equation (7.2) is satisfied for $t_{\text{lag}} \gtrsim 15.1$ days. Hence, if the public health response lag is 16 days or longer, then it is guaranteed that (regardless of the vaccination scenario or corresponding vaccination effort, $\phi_{\langle\text{model}\rangle}$) delaying will not be the individual equilibrium.

We emphasize that our estimate of 16 days as an upper bound for t^*_{lag} depends on a number of factors, including:

— the probability of an outbreak (a);
— the proportion of susceptibles infected in the initial outbreak (α); and
— the epidemiological model: the estimate is obtained using the SIR model, but adding an exposed class (SEIR) with parameters as in table 1 increases the critical lag. Repeating the calculation for the SEIR model yielded the upper bound $t^*_{\text{lag}} \leq 26.3$ days. The reason for this difference in critical lags is that, when the outbreak is seeded, all individuals initially infected begin their latent period simultaneously, and take on average 15 days to become infectious.

Thus, $t^*_{\text{lag}} < 16$ days should be regarded as a rough estimate at best. Nonetheless, the existence of a critical lag,

Figure 5. Variation of the effective critical lag $\widetilde{t^*_{\text{lag}}}$ (§7.5.2) with vaccination effort $\phi_{\langle\text{model}\rangle}$. (a) Effective critical lag versus percentage of the fair comparison vaccination effort when the fair comparison vaccination effort is defined. (b) Effective critical lag versus vaccination effort ϕ_{inst} when vaccination is instantaneous. (Online version in colour.)

beyond which it is impossible to reduce mortality by increasing vaccination effort, is an important consideration for public health agencies, in devising contingency plans for post-outbreak vaccination against diseases.

Note, however, that, in the case of a bioterrorist attack, an outbreak will probably not be discovered until individuals show symptoms, i.e. until someone's latent period has passed (12 days at a minimum). Taking this delayed detection into account, it follows that in order to avoid extending the mortality plateau to all feasible values of vaccination effort, ϕ_{const}, the response lag from discovery of the epidemic to the beginning of the post-outbreak vaccination response must, in practice, be substantially shorter than 26 days. This is in contrast to an accidental release, where public health authorities might know of the outbreak well before anyone has shown symptoms. In this latter case, because it is more likely that the critical lag has not been exceeded, it is especially important to begin the vaccination response as early as possible in order to reduce mortality.

Lastly, it is important to note that the effect of a response lag on the mortality plateau presupposes that both the vaccination effort and the response lag are known to the public in advance. This limits the applicability of this effect, because, in the case of a bioterrorist attack, the response lag probably depends on when an infective first shows symptoms (which introduces a stochastic effect). Further analysis would be needed to determine the effects of a stochastic response lag on individual behaviour, and thus on mortality.

7.5.2. The effective critical lag, $\widetilde{t^*_{\text{lag}}}$

We have seen that if the response lag is longer than the critical lag ($t_{\text{lag}} > t^*_{\text{lag}}$), then no matter how large the vaccination effort ($\phi_{\langle\text{model}\rangle}$), it is impossible to reduce mortality. Of course, in practice, the vaccination effort cannot be arbitrarily large and will be constrained by public health resources. Given a maximum *feasible* vaccination effort, it would be helpful to know how long the response lag can be before the mortality plateau extends to all feasible levels of vaccination effort.

To address this issue, we define the *effective critical lag*, $\widetilde{t^*_{\text{lag}}}$, to be the minimal response lag, such that the individual equilibrium is no longer to delay (i.e. $p_i > 0$) *given a maximum feasible vaccination effort* $\phi_{\langle\text{model}\rangle}$. Thus, the critical lag t^*_{lag} is the limit of $\widetilde{t^*_{\text{lag}}}$ as the maximum feasible vaccination effort becomes arbitrarily large.

In figure 5, we plot the effective critical lag, $\widetilde{t^*_{\text{lag}}}$, against the vaccination effort, $\phi_{\langle\text{model}\rangle}$, for the various models

examined in this paper. For the models for which fair comparison values of $\phi_{\langle \text{model} \rangle}$ are well defined (see §6.2), we used these as estimates for feasible vaccination efforts. However, because the fair comparison level of vaccination effort is a crude estimate for the range of feasible vaccination efforts, in figure 5a, we plot the effective critical lag at values of $\phi_{\langle \text{model} \rangle}$ ranging from 50% to 150% of the fair comparison levels of vaccination efforts for the various models, in increments of 10% of the fair comparison level of $\phi_{\langle \text{model} \rangle}$.

The instantaneous vaccination model was the only model for which a fair comparison value of vaccination effort ϕ_{inst} could not be defined (see §6.2). For this model, we show the effective critical lag $\widetilde{t^*_{\text{lag}}}$ for ϕ_{inst} ranging from 0.8 to 1 (if $\phi_{\text{inst}} < 0.8$, then $\widetilde{t^*_{\text{lag}}} < 1$ day) in figure 5b.

We see in figure 5 that, for some vaccination scenarios, minimizing the response lag t_{lag} is essential: even a short lag extends the mortality plateau to all feasible vaccination effort levels, making it impossible to reduce mortality by increasing effort after the lag. We also note that, for some scenarios, a good estimate of the attainable vaccination effort is necessary, because the critical effective lag is very sensitive to the vaccination effort. These two facts further underline the importance of accurately modelling post-outbreak vaccination to inform public health decisions relating to post-outbreak contingency plans. When the response lag is longer than the effective critical lag ($t_{\text{lag}} \geq \widetilde{t^*_{\text{lag}}}$), the only plausible way for public health officials to decrease mortality (while allowing individuals to choose whether or not to vaccinate) is to reduce the relative mortality risk (by decreasing the probability of dying from vaccination, i.e. developing a safer vaccine).

7.5.3. The response lag should be minimized
Based on §§7.5.1 and 7.5.2, reducing the response lag lowers expected mortality and makes it easier to decrease mortality further:

— For vaccination efforts higher than the end of the mortality plateau, everyone will choose to delay vaccination (§7.2.1). From the discussion leading up to equation (7.1), it follows that, even in the best-case scenario where the epidemic is stopped immediately at $t = t_{\text{lag}}$, mortality will be no less than

$$r_{\text{i}}(I(t_{\text{lag}}) + R(t_{\text{lag}}))|_{p=0}, \qquad (7.3)$$

which increases with the response time t_{lag}. Thus, increasing the response lag increases the lowest attainable mortality (even if vaccination effort can be increased without bound).
— Increasing the response lag increases the vaccination effort at the end of the mortality plateau (i.e. the minimal vaccination effort beyond which increasing vaccination effort decreases mortality). Thus, longer response lags make it harder to achieve a decrease in mortality.

However, note that if a response time lower than the effective critical lag ($t_{\text{lag}} < \widetilde{t^*_{\text{lag}}}$) cannot be achieved, neither increasing the vaccination effort, $\phi_{\langle \text{model} \rangle}$, nor decreasing the response time, t_{lag}, can decrease mortality.

8. Conclusion
We have analysed five distinct scenarios (§2) associated with a potential smallpox outbreak triggered by a bioterrorist attack or accidental release. The scenarios differ in the factors that influence individuals' perception of risk and how a post-outbreak vaccination response plays out. We examined these scenarios both with and without an assumed lag between an outbreak starting and a public health response being initiated. Our work generalizes the analysis of Bauch *et al.* [4], who investigated a single scenario with a response lag of 14 days.

As in [4], we considered separately group interest (optimal strategies for minimizing overall mortality) and self-interest (stable strategies for individual choices with respect to pre-emptive vaccination). From each perspective, we obtained the (imposed or expected) pre-emptive vaccination coverage (p) for each scenario (the group optimum p_{g} in the case of group interest and the individual equilibrium p_{i} in the case of self-interest; figure 1).

Our principal conclusions are the following.

(1) For a given level of post-outbreak vaccination effort, the group optimum pre-emptive coverage is always greater than the individual equilibrium ($p_{\text{g}} > p_{\text{i}}$; figure 1) and the expected total mortality is always less if public health authorities impose the group optimum rather than letting individuals make their own vaccination decisions (figure 2a). If no outbreak occurs, then some people will die unnecessarily from pre-emptive vaccination. Given the difficulty of estimating the probability of an attack or accidental release, it would be hard for governments to justify an imposed pre-emptive vaccination policy for a disease like smallpox for which the vaccine can cause death.
(2) The number of vaccine doses required at the group optimum and individual equilibrium does not vary substantially as a function of vaccination effort (e.g. speed of vaccine distribution post-outbreak) for any of the scenarios (figure 2b). Consequently, the economic cost of vaccine production is not likely to play a significant role in policy decisions.
(3) Total expected mortality as a function of vaccination effort depends strongly on which scenario is considered (figure 2a). Some vaccination scenarios are affected by the public reaction to media reports on the epidemic's progress, whereas some (the instantaneous and constant rate vaccination scenarios) are under the direct control of public health authorities. To assist public health authorities preparing for potential outbreaks, further research is needed to determine which factors have the greatest influence on individuals' perception of risk and which post-outbreak vaccination strategies are most feasible.
(4) For any realistic vaccination scenario, there is a range of vaccination effort levels in which increasing vaccination effort does not reduce overall mortality. In this mortality plateau, increasing vaccination effort leads only to fewer people vaccinating pre-emptively, until the individual equilibrium becomes to delay vaccination (at which point it is possible to reduce mortality by increasing the vaccination effort). Thus, under voluntary vaccination, in order for public health authorities to expect to reduce mortality by increasing vaccination effort post-outbreak, their planned post-outbreak vaccination response must be so efficient that no one would choose to vaccinate pre-emptively ($p_{\text{i}} = 0$).
(5) Any lag between the beginning of an outbreak and the post-outbreak vaccination response makes it harder for higher vaccination effort levels to make a difference to overall mortality, and a large enough lag will make it

impossible to reduce mortality, *regardless* of the level of vaccination effort. Given a maximum feasible vaccination effort level, there is an effective critical lag, beyond which it is impossible to reduce mortality by increasing vaccination effort. The dependence on the post-outbreak vaccination scenario, of both the effective critical lag at feasible levels of vaccination effort and the effect of changes in vaccination effort on the effective critical lag, further highlights the importance of researching realistic post-outbreak vaccination responses.

It is not possible to know with certainty how governments and health agencies will react, or how individuals will behave, in the event of an outbreak. However, the above-mentioned conclusions are based on our analysis of five distinct post-outbreak scenarios (and some model features that are much more generic), so it seems likely that our conclusions would remain valid if further plausible scenarios were considered.

References

1. Fenner F. 1988 Smallpox and its eradication, Parts 1–14. In *History of international public health*, vol. 6. Geneva, Switzerland: World Health Organization.

2. Koplow DA. 2004 *Smallpox: the fight to eradicate a global scourge*. Oakland, CA: University of California Press.

3. Christensen J. 2014 *CDC: smallpox found in NIH storage room is alive*. http://www.cnn.com/2014/07/11/health/smallpoxfound-nih-alive/ (accessed 12 August 2014).

4. Bauch CT, Galvani AP, Earn DJD. 2003 Group interest versus self-interest in smallpox vaccination policy. *Proc. Natl Acad. Sci. USA* **100**, 10564–10567. (doi:10.1073/pnas.1731324100)

5. Bauch CT, Earn DJD. 2004 Vaccination and the theory of games. *Proc. Natl Acad. Sci. USA* **101**, 13 391–13 394. (doi:10.1073/pnas.0403823101)

6. Anderson RM, May RM. 1991 *Infectious diseases of humans: dynamics and control*. Oxford, UK: Oxford University Press.

7. Eichner M, Dietz K. 2003 Transmission potential of smallpox: estimates based on detailed data from an outbreak. *Am. J. Epidemiol.* **158**, 110–117. (doi:10.1093/aje/kwg103)

8. Gani R, Leach S. 2001 Transmission potential of smallpox in contemporary populations. *Nature* **414**, 748–751. (doi:10.1038/414748a)

9. Krylova O. 2011 Predicting epidemiological transitions in infectious disease dynamics: smallpox in historic London (1664–1930). PhD thesis, McMaster University, Canada.

10. Kaplan EH, Craft DL, Wein LM. 2002 Emergency response to a smallpox attack: the case for mass vaccination. *Proc. Natl Acad. Sci. USA* **99**, 10 935–10 940. (doi:10.1073/pnas.162282799)

11. Fudenberg D, Tirole J. 1991 *Game theory*. Cambridge, MA: MIT Press.

12. Maynard Smith J. 1982 *Evolution and the theory of games*. Cambridge, UK: Cambridge University Press.

13. Krylova O, Earn DJD. 2013 Effects of the infectious period distribution on predicted transitions in childhood disease dynamics. *J. R. Soc. Interface* **10**, 20130098. (doi:10.1098/rsif.2013.0098)

14. World Health Organization. 2014 *World health statistics 2014*. Geneva, Switzerland: WHO.

15. Hammarlund E, Lewis MW, Hansen SG, Strelow LI, Nelson JA, Sexton GJ, Hanifin JM, Slifka MK. 2003 Duration of antiviral immunity after smallpox vaccination. *Nat. Med.* **9**, 1131–1137. (doi:10.1038/nm917)

16. Kermack WO, McKendrick AG. 1927 A contribution to the mathematical theory of epidemics. *Proc. R. Soc. Lond. A* **115**, 700–721. (doi:10.1098/rspa.1927.0118)

17. Ma J, Earn DJD. 2006 Generality of the final size formula for an epidemic of a newly invading infectious disease. *Bull. Math. Biol.* **68**, 679–702. (doi:10.1007/s11538-005-9047-7)

18. Earn DJD, Andrews PW, Bolker BM. 2014 Population-level effects of suppressing fever. *Proc. R. Soc. B* **281**, 20132570. (doi:10.1098/rspb.2013.2570)

19. Weisstein EW. Lambert W-function. From MathWorld: a Wolfram Web Resource. http://mathworld.wolfram.com/LambertW-Function.html (accessed 17 April 2015).

20. Corless RM, Gonnet GH, Hare DEG, Jeffrey DJ, Knuth DE. 1996 On the Lambert W function. *Adv. Comput. Math.* **5**, 329–359. (doi:10.1007/BF02124750)

21. McNeil Jr DG. 2013 Wary of attack with smallpox, U.S. buys up a costly drug. *The New York Times*. See http://www.nytimes.com/2013/03/13/health/us-stockpiles-smallpox-drug-in-case-of-bioterror-attack.html (accessed 12 August 2014).

22. Vink MA, Bootsma MCJ, Wallinga J. 2014 Serial intervals of respiratory infectious diseases: a systematic review and analysis. *Am. J. Epidemiol.* **180**, 865–875. (doi:10.1093/aje/kwu209)

23. Svensson A. 2007 A note on generation times in epidemic models. *Math. Biosci.* **208**, 300–311. (doi:10.1016/j.mbs.2006.10.010)

24. R Core Team. 2013 *R: a language and environment for statistical computing*. Vienna, Austria. See http://www.R-project.org/.

25. Soetaert K, Petzoldt T, Setzer RW. 2010 Solving differential equations in R: package deSolve. *J. Stat. Softw.* **33**, 1–25.

26. Sandholm WH. 2010 *Population games and evolutionary dynamics*. Economic Learning and Social Evolution. Cambridge, MA: MIT Press.

27. Bishop DT, Cannings C. 1978 A generalized war of attrition. *J. Theor. Biol.* **70**, 85–124. (doi:10.1016/0022-5193(78)90304-1)

28. Leach M, Fairhead J. 2007 *Vaccine anxieties: global science, child health and society*. Science in Society Series. London, UK: Earthscan.

29. Brown KF, Kroll JS, Hudson MJ, Ramsay M, Green J, Long SJ, Vincent CA, Fraser G, Sevdails N. 2010 Factors underlying parental decisions about combination childhood vaccinations including MMR: a systematic review. *Vaccine* **28**, 4235–4248. (doi:10.1016/j.vaccine.2010.04.052)

30. Gangarosa EJ, Galazka A, Wolfe C, Phillips L, Gangarosa R, Miller E, Chen RT, Gangarosa RE. 1998 Impact of anti-vaccine movements on pertussis control: the untold story. *Lancet* **351**, 356–361. (doi:10.1016/S0140-6736(97)04334-1)

31. Phillips CJ. 2008 *Health economics: an introduction for health professionals*. London, UK: John Wiley & Sons.

Game theory of pre-emptive vaccination before bioterrorism or accidental release of smallpox
Electronic Supplementary Material

Chai Molina and David J.D. Earn

Department of Mathematics and Statistics
McMaster University
Hamilton, Ontario, Canada, L8S 4K1

April 7, 2015 @ 17:51

APPENDICES

A Lambert W function

The standard final size relation, which can be derived from the SIR model [1] and many other epidemic models [2], is

$$Z = 1 - e^{-\mathcal{R}_0 Z}. \tag{S1}$$

Here, Z is the final size ($Z = 1 - S_\infty$) and $\mathcal{R}_0$ is the basic reproduction number. Z can be expressed explicitly as a function of $\mathcal{R}_0$ [2,3],

$$Z(\mathcal{R}_0) = 1 + \frac{1}{\mathcal{R}_0}\, W[-\mathcal{R}_0\, e^{-\mathcal{R}_0}], \tag{S2}$$

where the Lambert W function [4,5] is the inverse function of

$$f(W) = W\, e^W. \tag{S3}$$

Use of the Lambert W function is critical for our derivations of final size formulae for models we consider here. $W(x)$ is real for $x \geq -1/e \simeq -0.368$ and is two-valued for $-1/e < x < 0$. The upper "principal" branch, for which $W(x) \geq -1$, is denoted W_0 and the lower branch is denoted W_{-1}. See Figure S1.

Figure S1: The Lambert W function, showing the principal branch W_0 and the secondary branch W_{-1}.

3

B   Interpretation of vaccination effort parameters

The vaccination effort parameters are explained § 5. "Fair comparison" values for these parameters are derived in § 6.2 and listed in Table 3.

B.1 $\phi_{\mathbf{susc}}$

In § 6.2, we commented that ϕ_{susc} can be considered to be the probability per unit time of a delayer being vaccinated. To see this, note that the probability (p_{vacc}) of a susceptible delayer being vaccinated in the time interval $[t, t + \Delta t]$ is the ratio of the number of susceptibles vaccinated in that time interval, $V(t + \Delta t) - V(t)$, to the number of susceptibles present at the beginning of that time interval, $S(t)$. Thus,

$$p_{\text{vacc}} = \frac{V(t + \Delta t) - V(t)}{S(t)} = \frac{V(t + \Delta t) - V(t)}{\Delta t} \frac{1}{S(t)} \Delta t \,.$$

Since $\lim_{\Delta t \to 0} \frac{V(t+\Delta t)-V(t)}{\Delta t} = \dot{V} = \phi_{\text{susc}} S$, for small Δt, we have $p_{\text{vacc}} \approx \phi_{\text{susc}} \Delta t$. Thus, ϕ_{susc} is the (constant) probability per unit time of a delayer being vaccinated.

C   Convergence to disease–free equilibrium

In this appendix, we show that for all models considered, the epidemic must eventually die out (*i.e.,* the system converges to a disease-free equilibrium).

Consider the $SIRV$ model given by the differential equations

$$\dot{S} = -\beta SI - \dot{V} \,, \tag{S4a}$$

$$\dot{I} = \beta SI - \gamma I \,, \tag{S4b}$$

$$\dot{R} = \gamma I \,, \tag{S4c}$$

$$\dot{V} = f(t, S, I, R, V) \,, \tag{S4d}$$

where f is continuously differentiable and satisfies $f(t, S, I, R, V) \geq 0$, $f(t, 0, I, R, V) = 0$ whenever $t \geq 0$, $S \geq 0$, $I \geq 0, R \geq 0$, $V \geq 0$. From the fundamental existence and uniqueness theorem [6], there is a unique solution to Equation (S4) for any non-negative initial conditions $S(0) \geq 0$, $I(0) \geq 0$, $R(0) \geq 0$ and $V(0) \geq 0$. Suppose also that $S(0) + I(0) + R(0) + V(0) = 1$.

First, note that $S(t) \geq 0$ for all $t \geq 0$. To see this, suppose in order to derive a contradiction that $S(T) < 0$ for some $T > 0$. Then, since $S(t)$ is continuous, there must be some time $0 \leq \tau < T$ such that $S(\tau) = 0$. But because $\dot{S}|_{S=0} = 0$ it follows that $S(t) = 0$ for all $t \geq \tau$, which contradicts $S(T) < 0$.

Similarly, it follows that $I(t) \geq 0$. Consequently, $R(t)$ is nondecreasing in t, and in particular, $R(t) \geq 0$. Lastly, $\dot{V} \geq 0$ so $V(t) \geq 0$ as well.

Now, $\frac{\mathrm{d}}{\mathrm{d}t} \left(S(t) + I(t) + R(t) + V(t) \right) = 0$ for all t, so $S(0) + I(0) + R(0) + V(0) = 1$ implies $S(t) + I(t) + R(t) + V(t) = 1$ for all t. Consequently, $S(t)$, $I(t)$, $R(t)$ and $V(t)$ each lie in the interval $[0, 1]$ for all time.

In addition to being bounded, $S(t)$, $R(t)$ and $V(t)$ are monotonic (their time derivatives are non-positive) and therefore have a limit as $t \to \infty$. It follows that $I(t)$ also has such a limit ($I = 1 - S - V - R$). To see that this limit is 0, suppose instead that $I_\infty = \lim_{t \to \infty} I(t) > 0$. Then, $\lim_{t \to \infty} \dot{R} = \gamma I_\infty$. Thus, there exists a time t_* such that $\dot{R}(t) > \gamma I_\infty / 2$ for all $t_* < t$. This implies that the proportion in the recovered class increases at least linearly , and must eventually hit $R = 1$ (no later than at time $t_* + 2/(\gamma I_\infty)$) and be greater than 1 thereafter. However, this contradicts the fact that the proportion of the population in any class cannot exceed 1. Thus $I_\infty = \lim_{t \to \infty} I(t) = 0$.

A similar argument can be applied to the constant rate $SEIRV$ model by noting that

1. If $S(0) \geq 0$, $E(0) \geq 0$, $I(0) \geq 0$, $R(0) \geq 0$ and $V(0) \geq 0$, then S, E, I, R and V remain non-negative for all time.

2. If $S(0) + E(0) + I(0) + R(0) + V(0) = 1$, then $S + E + I + R + V = 1$ for all time.

3. $S(t) \to 0$ in finite time in this model. To see this, suppose in order to derive a contradiction, that $S(t) > 0$ for all time $t \geq 0$. Then, for all $t > t_{\text{lag}}$, $\dot{S} = \phi_{\text{const}}$, and thus $S(t) \geq \phi_{\text{const}}(t - t_{\text{lag}})$. Consequently, $S(t) > 1$ for all $t > t_{\text{lag}} + 1/\phi_{\text{const}}$, contradicting the fact that $S(t) \leq 1$ for all t.

4. Since $S(t) \to 0$ in finite time in this model, it follows that after a finite time $\dot{E} = -\sigma E$, implying that $\lim_{t \to \infty} E = 0$. Since R and V are monotonic and thus have a limit as $t \to \infty$, it follows that $\lim_{t \to \infty} I = \lim_{t \to \infty} 1 - S - E - R - V$ exists as well, and one can continue as before.

Lastly, a corollary of this convergence to the disease-free equilibrium is that $S_\infty = \lim_{t \to \infty} S(t)$ is well defined and

$$S_\infty < \frac{\gamma}{\beta} = \frac{1}{\mathcal{R}_0} \, . \tag{S5}$$

To see this, observe that since S is monotonic and bounded, it must converge to some finite limit within $[0, 1]$, so S_∞ is well defined. Next, note that $I(0) = \alpha(1 - p) > 0$ and $\lim_{t \to \infty} I(t) = I_\infty = 0$, so there is some time t_* at which $\dot{I}(t_*) < 0$ and so $S(t_*) < \gamma/\beta$. But $\dot{S} \leq 0$ and so for any $t_* < t$, we have $S(t) < \gamma/\beta$. Thus, Equation (S5) follows because of the monotonicity of S.

D   Calculation of π_1

In § 5, we stated that as pre-emptive vaccination approaches full coverage ($p \to 1$), the probability of a delayer being infected (π_p) approaches the proportion of susceptibles initially infected in an outbreak (α). Recalling the definition of π_1 in Equation (12), the claim is that for all the models considered

$$\pi_1 = \lim_{p \to 1^-} \pi_p = \alpha \, . \tag{S6}$$

To verify Equation (S6), first consider the SIRV models defined in Equation (9). The proportion of individuals who are eventually removed (R_∞) must be greater than the number

84 initially infected (Equation (10b)), so

$$R_\infty \geq I(0) = \alpha(1-p)\,. \tag{S7}$$

86 Thus from Equation (11a), we have $\pi_p \geq \alpha$ for any $p \in [0,1)$. It follows that $\pi_1 \geq \alpha$ if the
87 limit exists.
88   We now show that $\pi_1 \leq \alpha$. The basic reproduction number is $\mathcal{R}_0 = \beta/\gamma$ and the effective
89 reproduction number when the outbreak begins is (Equation (10a))

$$\mathcal{R}_{\text{eff}}(0) = \mathcal{R}_0 S(0) = \mathcal{R}_0 (1-p)(1-\alpha)\,. \tag{S8}$$

91 Thus, if $p > 1 - 1/\mathcal{R}_0$ then $\mathcal{R}_{\text{eff}}(0) < 1$, and

$$\lim_{p \to 1^-} \mathcal{R}_{\text{eff}}(0) = 0\,. \tag{S9}$$

93 To prove that $\pi_1 \leq \alpha$, we will show that

$$\pi_p \leq \frac{\alpha}{1 - \mathcal{R}_{\text{eff}}(0)}\,, \qquad \text{for all } p > 1 - \frac{1}{\mathcal{R}_0}\,. \tag{S10}$$

95 Equations (9b) and (S4c) imply that $\dot{R} = \gamma I = \beta S I - \dot{I}$. Hence,

$$R_\infty = \int_0^\infty \dot{R}\,\mathrm{d}t = \int_0^\infty \left(\beta S I - \dot{I}\right)\mathrm{d}t\,. \tag{}$$

97 But $S(t)$ decreases monotonically with t, and $I_\infty = 0$ (Appendix C), so

$$R_\infty \leq \beta S(0) \int_0^\infty I\,\mathrm{d}t + I(0) = \mathcal{R}_{\text{eff}}(0) \int_0^\infty \gamma I\,\mathrm{d}t + I(0) = \mathcal{R}_{\text{eff}}(0) R_\infty + \alpha(1-p)\,. \tag{S11}$$

99 Thus,

$$\left(1 - \mathcal{R}_{\text{eff}}(0)\right) R_\infty \leq \alpha(1-p)\,, \tag{S12}$$

101 and consequently, for any $p > 1 - 1/\mathcal{R}_0$,

$$\pi_p = \frac{R_\infty}{1-p} \leq \frac{\alpha}{1 - \mathcal{R}_{\text{eff}}(0)}\,. \tag{S13}$$

103 In the limit $p \to 1^-$, Equation (S9) implies $\pi_1 \leq \alpha$, as required.
104   To see that $\pi_1 = \alpha$ for the constant rate vaccination (SEIRV) model (Equation (29)), we
105 need only note that in this case,

$$R_\infty = \int_0^\infty \gamma I\,\mathrm{d}t = \int_0^\infty (\beta S I - \dot{I} - \dot{E})\,\mathrm{d}t \leq \mathcal{R}_0 S(0) \int_0^\infty \gamma I\,\mathrm{d}t + E(0)\,, \tag{S14}$$

107 where $E(0) = \alpha(1-p)$. Thus, Inequality (S11) holds for the SEIRV model as well, and the
108 remainder of the proof that $\pi_1 = \alpha$ is identical to the argument for SIRV models.

6

E Final size relations, π_p and ψ_p

E.1 Vaccination rate $\propto$ disease prevalence

E.1.1 Final size relations

A naïve model in which vaccination is proportional to prevalence is

$$\dot{S} = -\beta SI - \phi_{\mathrm{prev}}I \tag{S15a}$$

$$\dot{I} = \beta SI - \gamma I \tag{S15b}$$

$$\dot{R} = \gamma I \tag{S15c}$$

$$\dot{V} = \phi_{\mathrm{prev}}I\,. \tag{S15d}$$

However, Equation (S15a) is not biologically sensible, since if $S = 0$ and $I > 0$ it follows that $\dot{S} < 0$ and so S attains negative values. Thus, a more realistic model is obtained by replacing the vaccination rate $\phi_{\mathrm{prev}}I$ with $\phi_{\mathrm{prev}}f(S)I$, where f is a nondecreasing and smooth "cutoff function" such that $f(S) = 1$ except for $0 \le S < \delta$, and $f(0) = 0$. Thus, Equation (S15a) is replaced by

$$\dot{S} = -\beta SI - \phi_{\mathrm{prev}}f(S)I\,. \tag{S15a$'$}$$

For convenience, we also choose f to be an odd function, *i.e.*, $f(-S) = -f(S)$ (however, since negative values of S are not biologically feasible and are unattainable by this model if $S(0) \ge 0$, this has no effect on the dynamics of the model for biologically sensible initial conditions).

As $\delta \to 0$, $\dot{V}$ approaches $\phi_{\mathrm{prev}}\,\mathrm{sgn}(S)I$ and Equation (S15a$'$) approaches

$$\dot{S} = -\beta SI - \phi_{\mathrm{prev}}\,\mathrm{sgn}(S)I\,,$$

where

$$\mathrm{sgn}(x) = \begin{cases} -1 & \text{if } x < 0, \\ 0 & \text{if } x = 0, \\ 1 & \text{if } x > 0. \end{cases}$$

Thus, a more biologically sensible model where vaccination is proportional to prevalence is:

$$\dot{S} = -\beta SI - \phi_{\mathrm{prev}}\,\mathrm{sgn}(S)I \tag{S16a}$$

$$\dot{I} = \beta SI - \gamma I \tag{S16b}$$

$$\dot{R} = \gamma I \tag{S16c}$$

$$\dot{V} = \phi_{\mathrm{prev}}\,\mathrm{sgn}(S)I\,. \tag{S16d}$$

In the interior of the biologically meaningful domain,

$$\Delta = \{(S, I, R, V)|S \ge 0\,, I \ge 0\,, R \ge 0\,, V = 1 - S + I + R\}\,, \tag{S17}$$

the phase portrait for this model is similar to that of the original model and the dynamics change only as the hyper-plane $S = 0$ is reached. For this reason, we analyze the original

7

model (Equations (S15)) and make the necessary corrections to account for Equation (S16d) afterwards. We denote state-variable solutions to the original model (Equations (S15)) with a superscript 1, as in S^1, *etc.*

From Appendix C, we know that solutions of Equations (S15) converge to a disease-free equilibrium. Thus, we wish to obtain final size relations for this model. We proceed as follows:

From

$$\frac{\mathrm{d}R^1}{\mathrm{d}S^1} = -\frac{\gamma}{\beta S^1 + \phi_{\mathrm{prev}}}, \tag{S18}$$

we have

$$R^1_\infty = \frac{\gamma}{\beta} \ln\left(\frac{\beta S(0) + \phi_{\mathrm{prev}}}{\beta S^1_\infty + \phi_{\mathrm{prev}}}\right), \tag{S19}$$

where a subscript ∞ indicates the value of that variable at the end of the epidemic (recall that S(0) also depends on p). S^1_∞ is obtained by a similar trick.

$$\frac{\mathrm{d}I^1}{\mathrm{d}S^1} = -\frac{\beta S^1 - \gamma}{\beta S^1 + \phi_{\mathrm{prev}}} = -1 + \frac{\phi_{\mathrm{prev}} + \gamma}{\beta S^1 + \phi_{\mathrm{prev}}} \tag{S20}$$

$$I(t) - I(0) = S(0) - S^1(t) + \frac{\phi_{\mathrm{prev}} + \gamma}{\beta} \ln\left(\frac{\beta S^1(t) + \phi_{\mathrm{prev}}}{\beta S(0) + \phi_{\mathrm{prev}}}\right). \tag{S21}$$

As $t \to \infty$, we have

$$I_\infty - I(0) = S(0) - S^1_\infty + \frac{\phi_{\mathrm{prev}} + \gamma}{\beta} \ln\left(\frac{\beta S^1_\infty + \phi_{\mathrm{prev}}}{\beta S(0) + \phi_{\mathrm{prev}}}\right). \tag{S22}$$

Since $I^1_\infty = 0$ and $S(0) + I(0) = 1 - V(0) = 1 - p$,

$$S^1_\infty = (1 - p) + \frac{\phi_{\mathrm{prev}} + \gamma}{\beta} \ln\left(\frac{\beta S^1_\infty + \phi_{\mathrm{prev}}}{\beta S(0) + \phi_{\mathrm{prev}}}\right) = (1 - p) - \frac{\phi_{\mathrm{prev}} + \gamma}{\gamma} R^1_\infty. \tag{S23}$$

Let

$$w(x) = (1 - p) + \frac{\phi_{\mathrm{prev}} + \gamma}{\beta} \ln\left(\frac{\beta x + \phi_{\mathrm{prev}}}{\beta(1 - p)(1 - \alpha) + \phi_{\mathrm{prev}}}\right). \tag{S24}$$

We seek solutions to $S^1_\infty = w(S^1_\infty)$ in the range $S^1_\infty \in [0, 1]$. We note that no solutions of Equation (S15) cross the S-nullcline, $S = -\phi_{\mathrm{prev}}/\beta$, and so solutions to Equation (S23) are in the range $[-\phi_{\mathrm{prev}}/\beta, 1]$.

It is possible to use Equation (S23) to find which initial coverage causes solutions of Equation (S15) to hit the $S = 0$ hyper-plane, as they will be those for which $S^1_\infty \leq 0$. As long as this does not occur, Equations (S19), (S22) and (S23) are valid also for the modified system (Equations (S16)).

From Equation (S23), we have

$$S^1_\infty = -\frac{1}{\beta}\left(\phi_{\mathrm{prev}} + (\gamma + \phi_{\mathrm{prev}}) W_i\left(-\frac{\beta S(0) + \phi_{\mathrm{prev}}}{\gamma + \phi_{\mathrm{prev}}} e^{-\frac{\beta(1-p) + \phi_{\mathrm{prev}}}{\gamma + \phi_{\mathrm{prev}}}}\right)\right),$$

where $i = 0$ or -1 specifies the branch of the Lambert W function. To determine which branch of W gives the correct final size, observe that $S^1_\infty < \gamma/\beta$ for any initial condition (in the biologically meaningful domain). This follows from the following argument: If $S(0) \leq \gamma/\beta$, since S is non-increasing and $\dot{S} < 0$ at time $t = 0$ (since also $I(0) > 0$), we are done. If $S(0) > \gamma/\beta$, we note that I is increasing for any S such that $S > \gamma/\beta$. But we have seen that $I_\infty = 0$. Thus, at some point in time, $S < \gamma/\beta$, and since S is non-increasing, we have $S^1_\infty < \gamma/\beta$. From this we see that it is necessary to use the principal branch, W_0 (rather than W_{-1}, which satisfies $W_{-1}(x) \leq -1$ for all x in its domain of definition, that is $(-1/e, 0)$). Thus,

$$S^1_\infty = -\frac{1}{\beta}\left(\phi_{\text{prev}} + (\gamma + \phi_{\text{prev}})\, W_0\left(-\frac{\beta S(0) + \phi_{\text{prev}}}{\gamma + \phi_{\text{prev}}} e^{-\frac{\beta(1-p)+\phi_{\text{prev}}}{\gamma+\phi_{\text{prev}}}}\right)\right). \tag{S25}$$

For convenience, we rewrite Equations (S19), (S22) and (S23) to give:

$$\ln\left(\frac{\beta S(0) + \phi_{\text{prev}}}{\beta S^1_\infty + \phi_{\text{prev}}}\right) = \frac{\beta}{\phi_{\text{prev}} + \gamma}\left(1 - p - S^1_\infty\right), \tag{S26}$$

and

$$R^1_\infty = \frac{\gamma}{\beta}\ln\left(\frac{\beta S(0) + \phi_{\text{prev}}}{\beta S^1_\infty + \phi_{\text{prev}}}\right) = \frac{\gamma}{\phi_{\text{prev}} + \gamma}\left(1 - p - S^1_\infty\right). \tag{S27}$$

Thus,

$$V^1_\infty = 1 - R^1_\infty - S^1_\infty$$

$$= 1 - \frac{\gamma}{\phi_{\text{prev}} + \gamma}\left(1 - p - S^1_\infty\right) - S^1_\infty$$

$$= \frac{\phi_{\text{prev}}}{\gamma + \phi_{\text{prev}}}(1 - S^1_\infty) + \frac{\gamma}{\gamma + \phi_{\text{prev}}}p. \tag{S28}$$

To see when we can use $S_\infty = S^1_\infty$, $R_\infty = R^1_\infty$ and $V_\infty = V^1_\infty$, it is necessary to find when Equation (S25) yields a negative S^1_∞. First, we evaluate how S_∞ changes with p. To find $\partial_p S^1_\infty$, apply $\partial_p := \frac{\partial}{\partial p}$ to Equation (S23), to get (recall that $S(0) = (1 - \alpha)(1 - p)$, so $\partial_p S(0) = -(1 - \alpha)$)

$$\partial_p S^1_\infty = \frac{\gamma + \phi_{\text{prev}}}{\beta}\left[\frac{\beta(1-\alpha)}{\beta S(0) + \phi_{\text{prev}}} + \frac{\beta \partial_p S^1_\infty}{\beta S^1_\infty + \phi_{\text{prev}}}\right] - 1 \tag{S29}$$

$$\left(1 - \frac{\gamma + \phi_{\text{prev}}}{\beta S^1_\infty + \phi_{\text{prev}}}\right)\partial_p S^1_\infty = \frac{(\gamma + \phi_{\text{prev}})(1-\alpha)}{\beta S(0) + \phi_{\text{prev}}} - 1 \tag{S30}$$

$$\partial_p S^1_\infty = \left(\frac{(\gamma + \phi_{\text{prev}})(1-\alpha)}{\beta S(0) + \phi_{\text{prev}}} - 1\right) / \left(1 - \frac{\gamma + \phi_{\text{prev}}}{\beta S^1_\infty + \phi_{\text{prev}}}\right) \tag{S31}$$

Since $S^1_\infty < \gamma/\beta$, it follows that $1 - (\gamma + \phi_{\text{prev}})/(\beta S^1_\infty + \phi_{\text{prev}}) < 0$. Thus,

$$\text{sgn}(\partial_p S^1_\infty) = \text{sgn}\left[\beta S(0) + \phi_{\text{prev}} - (\gamma + \phi_{\text{prev}})(1 - \alpha)\right], \tag{S32}$$

9

and since $S(0) = (1-p)(1-\alpha)$, we have:

$$\operatorname{sgn} \partial_p S_\infty^1 = \begin{cases} 1 & \text{if } p_m > p \\ 0 & \text{if } p_m = p, \\ -1 & \text{if } p_m < p, \end{cases} \tag{S33}$$

where the local maximum is attained at

$$p = p_m := 1 + \frac{\phi_{\mathrm{prev}} - (\gamma + \phi_{\mathrm{prev}})(1-\alpha)}{\beta(1-\alpha)} = 1 + \frac{\alpha\phi_{\mathrm{prev}} - \gamma(1-\alpha)}{\beta(1-\alpha)}. \tag{S34}$$

Observe that $p_m \in [0,1] \iff \alpha\phi_{\mathrm{prev}} \leq \gamma(1-\alpha)$ and $\alpha\phi_{\mathrm{prev}} \geq (\gamma - \beta)(1-\alpha)$. However, the second condition, which is necessary to ensure $p_m \geq 0$, is trivially satisfied whenever $\beta/\gamma = \mathcal{R}_0 \geq 1$. Thus, if $\mathcal{R}_0 \geq 1$, then $p_m \in [0,1]$ *iff*

$$\alpha\phi_{\mathrm{prev}} \leq \gamma(1-\alpha). \tag{S35}$$

The maximum value of S_∞^1 is thus:

$$\max_{p \in [0,1]} S_\infty^1 = -\frac{1}{\beta}\left(\phi_{\mathrm{prev}} + (\gamma + \phi_{\mathrm{prev}})\, W_0\left(-\frac{\beta S(0) + \phi_{\mathrm{prev}}}{\gamma + \phi_{\mathrm{prev}}} e^{-\frac{\phi_{\mathrm{prev}} - \gamma(1-\alpha)}{(\gamma + \phi_{\mathrm{prev}})(1-\alpha)}}\right)\right). \tag{S36}$$

Now solving for $S_\infty^1 = 0$ using Equation (S25), we have

$$p_0(i) = 1 + \frac{\phi_{\mathrm{prev}}}{\beta(1-\alpha)} + \frac{\gamma + \phi_{\mathrm{prev}}}{\beta}\, W_i\left(-\frac{\phi_{\mathrm{prev}}}{(1-\alpha)(\gamma + \phi_{\mathrm{prev}})} e^{-\frac{\phi_{\mathrm{prev}}}{(1-\alpha)(\gamma + \phi_{\mathrm{prev}})}}\right) \tag{S37}$$

for $i = 0$ or -1. Note that for $\phi_{\mathrm{prev}} > 0$, Equation (S37) gives two values for p_0; we cannot simply cancel out the operation of W with xe^x, since in this case $x = -\frac{\phi_{\mathrm{prev}}}{(1-\alpha)(\phi_{\mathrm{prev}} + \gamma)} < 0$ and W is not univalued for negative arguments. Instead, we have two possibilities for $W\left(\frac{\phi_{\mathrm{prev}}}{(\alpha-1)(\gamma + \phi_{\mathrm{prev}})} e^{\frac{\phi_{\mathrm{prev}}}{(\alpha-1)(\gamma + \phi_{\mathrm{prev}})}}\right)$ corresponding to the two branches, W_0 and W_{-1}.

If $\alpha\phi_{\mathrm{prev}} < (1-\alpha)\gamma$, then $W_0\left(-\frac{\phi_{\mathrm{prev}}}{(1-\alpha)(\gamma + \phi_{\mathrm{prev}})} e^{-\frac{\phi_{\mathrm{prev}}}{(1-\alpha)(\gamma + \phi_{\mathrm{prev}})}}\right) = -\frac{\phi_{\mathrm{prev}}}{(1-\alpha)(\gamma + \phi_{\mathrm{prev}})}$, which gives $p_0(0) = 1$. If $\alpha\phi_{\mathrm{prev}} \geq (1-\alpha)\gamma$ then similarly $p_0(-1) = 1$. This is in agreement with the fact that if $p = 1$, $S(0) = 0$, and so $S_\infty^1 = 0$.

There are now three cases, which we express as two main cases, the second of which has two subcases:

- if $p_m \geq 1$ (which happens *iff* $\alpha\phi_{\mathrm{prev}} \geq (1-\alpha)\gamma$), then $S_\infty^1 \leq 0 \quad \forall p \in [0,1]$. This follows since if $p_m \geq 1$ then $p_0(-1) = 1 \leq p_m \leq p_0(0)$. Thus because S_∞^1 is increasing for $p < p_m$, so for $p \in [0,1]$, $S_\infty^1 \leq S_\infty^1|_{p=1} = 0$. In this case, S_∞ is not given by S_∞^1, but is simply $S_\infty = 0$.

- If $p_m \in (0,1)$ then $S_\infty^1|_{p_m} > S_\infty^1|_{p=1} = 0$ and $p_0(-1) < p_m$.

10

227   – If $0 \leq p_0(-1)$ (and $p_0(-1) < p_m < 1$) then

228
$$S_\infty = \begin{cases} 0 & \text{if } p < p_0(-1), \\ S_\infty^1 & \text{if } p_0(-1) \leq p\,. \end{cases} \tag{S38}$$

229   – If $p_0(-1) \leq 0$ then $S_\infty^1 \geq 0 \quad \forall p \in [0,1]$ and so $S_\infty = S_\infty^1$ for any $p \in [0,1]$.

230   In all but the very last sub-case, it is also necessary to adjust our formulae for the final
231 sizes of the removed and vaccinated compartments, R_∞ and V_∞, for the values of p for which
232 $S_\infty = 0$. Qualitatively, this adjustment is necessary because, when $\delta \to 0^+$, if a solution
233 reaches $S = 0$ in finite time, S remains 0, while I decays exponentially to 0. However, the
234 solutions of Equations (S15) are only identical to those of Equations (S16) so long as $S > 0$.
235 Moreover, once $S = 0$, V remains constant and all the infectives move into the recovered
236 compartment, which is not the case for solutions of Equations (S15).

     To find formulas for R_∞ and V_∞, fix $p \in [0,1)$ and let t_0 be the first time at which no
susceptibles remain ($S(t_0) = S^1(t_0) = 0$). Then Equations (S15) are valid for any $t < t_0$. We
now have

$$R(t) = \frac{\gamma}{\beta} \ln \left(\frac{\beta S(0) + \phi_{\text{prev}}}{\beta S(t) + \phi_{\text{prev}}} \right)$$

$$I(t) = I(0) + S(0) - S(t) + \frac{\phi_{\text{prev}} + \gamma}{\beta} \ln \left(\frac{\beta S(t) + \phi_{\text{prev}}}{\beta S(0) + \phi_{\text{prev}}} \right),$$

in a manner analogous to Equation (S19) and Equation (S22). These equations depend on
$S = S(t)$ in a way that is continuous at $S = 0$, and so taking $t \to t_0$ is equivalent to taking
$S \to 0$:

$$R(t_0) = \frac{\gamma}{\beta} \ln \left(\frac{\beta S(0) + \phi_{\text{prev}}}{\phi_{\text{prev}}} \right) \tag{S39}$$

$$I(t_0) = I(0) + S(0) + \frac{\phi_{\text{prev}} + \gamma}{\beta} \ln \left(\frac{\phi_{\text{prev}}}{\beta S(0) + \phi_{\text{prev}}} \right). \tag{S40}$$

237 When $S = 0$, I decays exponentially to 0, until all the infectives present at t_0 transition into
238 the removed class, R. Thus, we have

239
$$R_\infty = R(t_0) + I(t_0) = 1 - p - \frac{\phi_{\text{prev}}}{\beta} \ln \left(\frac{\beta}{\phi_{\text{prev}}} S(0) + 1 \right). \tag{S41}$$

240   Next, we know that once $S = 0$, V does not change either, since there are no more
241 susceptibles to be vaccinated. Thus,

242
$$V_\infty = V(t_0) = 1 - R(t_0) - I(t_0) = 1 - R_\infty = p + \frac{\phi_{\text{prev}}}{\beta} \ln \left(\frac{\beta}{\phi_{\text{prev}}} S(0) + 1 \right) \tag{S42}$$

11

Figure S2: The proportion of individuals remaining susceptible at the end of the epidemic, S_∞, as a function of the proportion of the population vaccinated preemptively, p, for the model in which vaccination rate is proportional to prevalence. The line $y(p) = (1-\alpha)(1-p)$ is overlaid in red. We take the proportion of susceptibles initially infected, α, to be the estimated value in the left panel ($\alpha = 1.72 \times 10^{-5}$) and a much larger value for comparison in the right panel ($\alpha = 0.1$); the remaining model parameters are as in Table 1. See § E.1.2.

To summarize our results so far,

$$S_\infty = \begin{cases} 0 & \text{if } p < p_0 \text{ or } 1 \le p_m, \\ S_\infty^1 & \text{if } p_0 \le p \le 1, \end{cases} \tag{S43a}$$

$$R_\infty = \begin{cases} 1 - p - \frac{\phi_{\text{prev}}}{\beta} \ln\left(\frac{\beta}{\phi_{\text{prev}}} S(0) + 1\right) & \text{if } p < p_0 \text{ or } 1 \le p_m, \\ \frac{\gamma}{\gamma + \phi_{\text{prev}}} \left(1 - p - S_\infty^1\right) & \text{if } p_0 \le p \le 1, \end{cases} \tag{S43b}$$

$$V_\infty = \begin{cases} p + \frac{\phi_{\text{prev}}}{\beta} \ln\left(\frac{\beta}{\phi_{\text{prev}}} S(0) + 1\right) & \text{if } p < p_0 \text{ or } 1 \le p_m, \\ \frac{1}{\gamma + \phi_{\text{prev}}} \left(\phi_{\text{prev}}(1 - S_\infty^1) + \gamma p\right) & \text{if } p_0 \le p \le 1, \end{cases} \tag{S43c}$$

where S_∞^1 is given by Equation (S25).

E.1.2 Qualitative behaviour of S_∞^1 for high vaccine coverage

Qualitatively, observe that for high values of p, $S_\infty^1 \approx (1-\alpha)(1-p)$ (see Figure S2). This is because when $p > p_d := 1 - \frac{\gamma}{\beta(1-\alpha)}$ then $S(0) < \gamma/\beta$, in which case I decays to 0 monotonically (the subscript "d" denotes decay of I). Now in this case, S decreases at least

12

as fast as it does in the vaccination-less SIR model, and so I decreases at least as fast as in the vaccination-less case too. Because S is monotonically decreasing, I decays faster than $I(0)e^{(\beta S(0)-\gamma)t}$. Because I decays at least exponentially, S hardly changes over the course of the epidemic, and so we see an approximately linear decay in $S^1_\infty \approx S(0) = (1-\alpha)(1-p)$ to 0 as we increase p. This last phenomenon is related to the herd immunity effect in the standard SIR model: when the entire population is susceptible, in the absence of post-outbreak vaccination ($\phi_{\mathrm{prev}} = 0$), the critical vaccine coverage which stops the epidemic from taking off is $p = 1 - \frac{1}{\mathcal{R}_{\mathrm{eff}}} = 1 - \frac{\gamma}{\beta(1-\alpha)}$. But note, moreover, that the maximal value of S^1_∞ is not attained at p_d. Rather, we see that

$$p_m - p_d = \frac{\alpha(\phi_{\mathrm{prev}} + \gamma)}{\beta(1-\alpha)} > 0 \,. \tag{S44}$$

This is because even when $p > p_d$ and I immediately decays to 0 (starting at $t = 0$), there are still some susceptibles converted into vaccinated individuals, due to $I > 0$. This number of susceptibles lost to vaccination decreases as p is increased, since this decreases $I(0)$ as well. Thus, for $p > p_d$, initially S_∞ increases with p. Only when $p > p_m$ does the decrease in S_∞ due to more susceptibles being vaccinated pre-emptively take over.

E.1.3 π_p decreases and ψ_p increases with p when $p_m \geq 1$

Consider the first case above: if $p_m \geq 1$ (see Equation (S43)), then $S_\infty = 0$ and we have

$$V_\infty = p + \frac{\phi_{\mathrm{prev}}}{\beta} \ln\left(\frac{\beta}{\phi_{\mathrm{prev}}} S(0) + 1\right)$$

$$\psi_p = \frac{\phi_{\mathrm{prev}}}{\beta(1-p)} \ln\left(\frac{\beta}{\phi_{\mathrm{prev}}} S(0) + 1\right) \,.$$

Note that since $S_\infty = 0$, $\pi_p = 1 - \psi_p$. Letting $x = \frac{\beta}{\phi_{\mathrm{prev}}} S(0) = \frac{\beta(1-\alpha)}{\phi_{\mathrm{prev}}}(1-p)$,

$$\psi(x) = \psi_{p(x)} = (1-\alpha)\frac{\ln(x+1)}{x} \,,$$

so

$$\partial_p \psi_p = -\frac{\beta(1-\alpha)}{\phi_{\mathrm{prev}}} \frac{\partial \psi(x)}{\partial x} = -\frac{\beta(1-\alpha)}{\phi_{\mathrm{prev}}} \frac{x - (1+x)\ln(1+x)}{x^2(x+1)}$$

$$= -\frac{\beta(1-\alpha)}{\phi_{\mathrm{prev}}} \frac{\frac{\beta}{\phi_{\mathrm{prev}}} S(0) - (\frac{\beta}{\phi_{\mathrm{prev}}} S(0) + 1)\ln(\frac{\beta}{\phi_{\mathrm{prev}}} S(0) + 1)}{\left(\frac{\beta}{\phi_{\mathrm{prev}}} S(0)\right)^2 (\frac{\beta}{\phi_{\mathrm{prev}}} S(0) + 1)}$$

$$= -\frac{\phi_{\mathrm{prev}}(1-\alpha)}{\beta} \frac{\beta S(0) - (\beta S(0) + \phi_{\mathrm{prev}})\ln(\frac{\beta}{\phi_{\mathrm{prev}}} S(0) + 1)}{(S(0))^2 (\beta S(0) + \phi_{\mathrm{prev}})} \,. \tag{S45}$$

Since $x < (x+1)\ln(1+x) \quad \forall x > -1$, it follows that for $p \in [0,1)$, $\partial_p \psi_p > 0$ and consequently, $\partial_p \pi_p < 0$.

13

E.1.4   Behaviour of $p_0(-1)$ as $\phi_{\mathbf{prev}} \to 0^+$

Using Equation (S37), one can show that $\lim_{\phi_{\mathrm{prev}} \to 0^+} p_0(-1) = -\infty$. This follows because $\lim_{\phi_{\mathrm{prev}} \to 0^-} W_{-1}(x) = -\infty$. But because $p_0(-1) \to 1$ as $\phi_{\mathrm{prev}} \to \frac{\gamma(1-\alpha)}{\alpha}$, it follows that there is some value of ϕ_{prev} for which $p_0(-1) = 0$. This ϕ_{prev} can be found from Equation (S37), but the formula is not needed here.

However, we also note that $\phi_{\mathrm{prev}} < \frac{\gamma(1-\alpha)}{\alpha}$ (along with $\mathcal{R}_0 > 1$) implies $p_m \in (0,1)$, so for small ϕ_{prev}, we have $p_m \in (0,1)$ and $p_0(-1) < 0$ (in fact, as $\phi_{\mathrm{prev}} \to 0^+$, $p_m \to 1 - 1/\mathcal{R}_0$). Thus, for $\phi_{\mathrm{prev}} \to 0^+$ (small enough such that $p_0(-1) < 0$), $S_\infty^1 > 0$ for $p \in [0,1)$.

E.2   Vaccination rate $\propto$ incidence

The model equations are

$$\dot{S} = -\beta SI - \phi_{\mathrm{inc}} SI \tag{S46a}$$

$$\dot{I} = \beta SI - \gamma I \tag{S46b}$$

$$\dot{R} = \gamma I \tag{S46c}$$

$$\dot{V} = \phi_{\mathrm{inc}} SI \,. \tag{S46d}$$

Finding the final sizes for this model is somewhat similar to when vaccination is proportional to prevalence:

$$\frac{\mathrm{d}I}{\mathrm{d}S} = -\frac{\beta SI - \gamma I}{(\beta + \phi_{\mathrm{inc}}) SI} = \frac{\gamma}{\beta + \phi_{\mathrm{inc}}} \frac{1}{S} - \frac{\beta}{\beta + \phi_{\mathrm{inc}}} \tag{S47}$$

$$I(t) - I(0) = \frac{\gamma}{\beta + \phi_{\mathrm{inc}}} \ln\left(\frac{S(t)}{S(0)}\right) - \frac{\beta}{\beta + \phi_{\mathrm{inc}}} (S(t) - S(0)) \tag{S48}$$

$$-(1-p)\alpha = \frac{\gamma}{\beta + \phi_{\mathrm{inc}}} \ln\left(\frac{S_\infty}{(1-p)(1-\alpha)}\right) - \frac{\beta}{\beta + \phi_{\mathrm{inc}}} (S_\infty - (1-p)(1-\alpha)) \tag{S49}$$

$$S_\infty = \frac{\gamma}{\beta} \ln\left(\frac{S_\infty}{(1-p)(1-\alpha)}\right) + \left(1 + \frac{\phi_{\mathrm{inc}}}{\beta}\alpha\right)(1-p) \,, \tag{S50}$$

where Equation (S49) is obtained by taking $t \to \infty$ in Equation (S48). The solution of Equation (S50) is given explicitly by

$$S_\infty = -\frac{\gamma}{\beta} W_0\left(-\frac{\beta(1-p)(1-\alpha)}{\gamma} e^{-\frac{\beta + \phi_{\mathrm{inc}}\alpha}{\gamma}(1-p)}\right) \,, \tag{S51}$$

where we take the principle branch of the Lambert function, W_0, because solutions are in the range $S_\infty \in [0, \gamma/\beta]$ (see Equation (S5) in Appendix C). Note also that $S_\infty > 0$ *iff* $S(0) > 0$ (that is, $p < 1$ and $\alpha < 1$). Thus, $S = 0$ is not attainable in scenarios of interest here.

To find V_∞, we proceed similarly:

$$\dot{V} = -\frac{\phi_{\text{inc}}}{\beta + \phi_{\text{inc}}}\dot{S} \tag{S52}$$

$$V_\infty - V(0) = -\frac{\phi_{\text{inc}}}{\beta + \phi_{\text{inc}}}(S_\infty - S(0)) \tag{S53}$$

$$V_\infty - p = \frac{\phi_{\text{inc}}}{\beta + \phi_{\text{inc}}}((1-p)(1-\alpha) - S_\infty). \tag{S54}$$

At the end of the epidemic, $1 = R_\infty + S_\infty + V_\infty$, hence,

$$R_\infty = 1 - p + \frac{\phi_{\text{inc}}}{\beta + \phi_{\text{inc}}}(S_\infty - (1-p)(1-\alpha)) - S_\infty$$

$$= 1 - p - \frac{\phi_{\text{inc}}(1-p)(1-\alpha) + \beta S_\infty}{\beta + \phi_{\text{inc}}}. \tag{S55}$$

Thus,

$$\pi_p = \frac{R_\infty}{1-p} = 1 - \frac{\phi_{\text{inc}}}{\beta + \phi_{\text{inc}}}(1-\alpha) - \frac{\beta S_\infty}{(\beta + \phi_{\text{inc}})(1-p)} \tag{S56a}$$

$$\psi_p = \frac{V_\infty - p}{1-p} = \frac{\phi_{\text{inc}}}{\beta + \phi_{\text{inc}}}\left((1-\alpha) - \frac{S_\infty}{1-p}\right). \tag{S56b}$$

Note that whenever $S(0) > 0$, there are susceptible individuals left at the end of the epidemic, and so $\pi_p \neq 1 - \psi_p$.

Using $\partial_p\left(\frac{S_\infty}{1-p}\right) = \frac{(1-p)\partial_p S_\infty + S_\infty}{(1-p)^2}$ we have

$$\partial_p S_\infty = \frac{\gamma}{\beta}\left(\frac{\partial_p S_\infty}{S_\infty} + \frac{1}{1-p}\right) - \left(1 + \frac{\phi_{\text{inc}}}{\beta}\alpha\right)$$

$$\frac{\beta S_\infty - \gamma}{\beta S_\infty}\partial_p S_\infty = \frac{\gamma}{\beta(1-p)} - 1 - \frac{\phi_{\text{inc}}}{\beta}\alpha$$

$$\partial_p S_\infty = \frac{\gamma}{1-p}\frac{S_\infty}{\beta S_\infty - \gamma} - (\phi_{\text{inc}}\alpha + \beta)\frac{S_\infty}{\beta S_\infty - \gamma}$$

$$= \frac{\gamma - (\phi_{\text{inc}}\alpha + \beta)(1-p)}{(1-p)}\frac{S_\infty}{\beta S_\infty - \gamma}$$

$$(1-p)\partial_p S_\infty + S_\infty = \frac{(\beta S_\infty - (1-p)(\beta + \phi_{\text{inc}}\alpha))S_\infty}{\beta S_\infty - \gamma}$$

$$\partial_p\left(\frac{S_\infty}{1-p}\right) = \frac{(\beta S_\infty - (1-p)(\beta + \phi_{\text{inc}}\alpha))S_\infty}{\beta S_\infty - \gamma}\frac{1}{(1-p)^2}. \tag{S57}$$

From Equation (S50)

$$\beta S_\infty - (1-p)(\beta + \phi_{\text{inc}}\alpha) = \gamma \ln\left(\frac{S_\infty}{S(0)}\right) < 0 \tag{S58}$$

15

because $S_\infty < S(0)$ (unless $S(0)$ or $I(0)$ is 0, in which case an outbreak cannot take place).

Thus $\partial_p \left(\frac{S_\infty}{1-p} \right) > 0$ and so

$$\partial_p \pi_p < 0 \tag{S59}$$

$$\partial_p \psi_p < 0 \,. \tag{S60}$$

Note also that S_∞ attains a local maximum (in p) at

$$p_m = 1 - \gamma/(\phi_{\text{inc}}\alpha + \beta) \,. \tag{S61}$$

$p_m < 0$ for $\gamma > \phi_{\text{inc}}\alpha + \beta$, in which case S_∞ decreases with p on the interval $[0,1]$. This can only happen when $\gamma > \beta$, that is when $\mathcal{R}_0 < 1$, implying that for any disease which can spread in the population (with no vaccination), pre-emptive vaccination initially raises, then lowers the proportion of susceptibles remaining at the end of the epidemic. The maximum level of remaining susceptibles is

$$S_\infty|_{p=p_m} = -\frac{\gamma}{\beta} \, W_0 \left(-\frac{\beta(1-\alpha)}{(\phi_{\text{inc}}\alpha + \beta)e} \right) \,. \tag{S62}$$

However, R_∞ is more informative, since susceptibles can be depleted by either infection or vaccination, and so fewer remaining susceptibles does not necessarily imply a larger epidemic, nor does it imply that more individuals were vaccinated. However,

$$\partial_p R_\infty = \partial_p \left((1-p)\pi_p \right) = -\pi_p + (1-p)\partial_p \pi_p < 0 \,, \tag{S63}$$

which shows that increasing pre-emptive vaccine coverage decreases the size of the epidemic, as expected.

E.3   Vaccination rate $\propto$ proportion still susceptible

The model equations are

$$\dot{S} = -\beta SI - \phi_{\text{susc}}S \tag{S64a}$$

$$\dot{I} = \beta SI - \gamma I \tag{S64b}$$

$$\dot{R} = \gamma I \tag{S64c}$$

$$\dot{V} = \phi_{\text{susc}}S \,. \tag{S64d}$$

In this case, a similar strategy to the one we employed for the case where vaccination is proportional to prevalence doesn't quite work. Calculating $S_\infty(I(0))$ is not enough, since we do not know how the remainder of the population is partitioned between the removed and vaccinated classes at the end of the epidemic. The following calculations are also helpful but insufficient:

$$\frac{\dot{I}}{I} = \beta S - \gamma = \frac{\beta}{\phi_{\text{susc}}}\dot{V} - \gamma \tag{S65}$$

$$\frac{\dot{S}}{S} = -\beta I - \phi_{\text{susc}} = -\frac{\beta}{\gamma}\dot{R} - \phi_{\text{susc}} \,, \tag{S66}$$

16

370 so

$$\ln\left(\frac{I(t)}{I(0)}\right) = \frac{\beta}{\phi_{\text{susc}}}(V(t) - V(0)) - \gamma t \tag{S67}$$

$$\ln\left(\frac{S(t)}{S(0)}\right) = -\frac{\beta}{\gamma}(R(t) - R(0)) - \phi_{\text{susc}}t\,. \tag{S68}$$

374 However, it is not possible to extract V_∞ and R_∞ from here because phase-portrait arguments
375 show that I and S tend to 0 as $t \to \infty$ (this is also implied by Equations (S67) and (S68)),
376 thus both sides of these equations diverge as $t \to \infty$.
377   Nonetheless, a similar method to the one employed in Appendix E.2 yields a relation
378 between $S(t)$ and $I(t)$ from which, using the previous relations, a relation between $R(t)$ and
379 $V(t)$ can be obtained. These will not diverge as $t \to \infty$ (they are bounded), so any divergent
380 components must cancel out.

$$\frac{\mathrm{d}S}{\mathrm{d}I} = -\frac{(\beta I + \phi_{\text{susc}})S}{(\beta S - \gamma)I} \tag{S69}$$

$$\frac{(\beta S - \gamma)}{S}\mathrm{d}S = -\frac{(\beta I + \phi_{\text{susc}})}{I}\mathrm{d}I \tag{S70}$$

$$(\beta - \frac{\gamma}{S})\mathrm{d}S = -(\beta + \frac{\phi_{\text{susc}}}{I})\mathrm{d}I \tag{S71}$$

$$\beta(S(t) - S(0)) - \gamma\ln\left(\frac{S(t)}{S(0)}\right) = -\beta(I(t) - I(0)) - \phi_{\text{susc}}\ln\left(\frac{I(t)}{I(0)}\right) \tag{S72}$$

386 from which we get:

$$S(t) = -\frac{\gamma}{\beta}\,W\left(-\frac{\beta}{\gamma}e^{\frac{\beta}{\gamma}(I(t)-I(0)-S(0))}\left(\frac{I(t)}{I(0)}\right)^{\frac{\phi_{\text{susc}}}{\gamma}}S(0)\right)\,. \tag{S73}$$

388 By taking the limit $t \to \infty$ in Equation (S73), we see that $S_\infty = 0$, and conseqently,
389 $\psi_p = 1 - \pi_p$.
390   We now determine under which conditions each of the two branches of the Lambert W
391 function is used in Equation (S73). First, note that

$$S(I) = -\frac{\gamma}{\beta}\,W(z(p))$$

$$z(I) = -\frac{\beta}{\gamma}e^{\frac{\beta}{\gamma}(I(t)-I(0)-S(0))}\left(\frac{I(t)}{I(0)}\right)^{\frac{\phi_{\text{susc}}}{\gamma}}S(0)$$

$$z(I(0)) = -\frac{\beta}{\gamma}S(0)e^{-\frac{\beta}{\gamma}S(0)}\,.$$

396 For $I = I(0)$, we expect to get $W(-\frac{\beta}{\gamma}S(0)) = -\frac{\beta}{\gamma}S(0)$ so that $S(I = I(0)) = S(t = 0)$.
397 We know that $S(0) > \frac{\gamma}{\beta}$ which implies that for $t = 0$, we must use W_1. Because $S(t)$
398 monotonically decreases to 0 as $t \to 0$, we know that the branch W_1 is used until the peak

17

prevalence is attained (at which time $S = \gamma/\beta$), and then the principal branch W_0 is used. Now,

$$
\begin{aligned}
\frac{\mathrm{d}R}{\mathrm{d}I} &= \frac{\gamma I}{\beta S I - \gamma I} \\
&= \frac{\gamma}{\beta S - \gamma} \\
&= \frac{-1}{W\left(-\frac{\beta}{\gamma} e^{\frac{\beta}{\gamma}(I - I(0) - S(0))} \left(\frac{I}{I(0)}\right)^{\frac{\phi_{\mathrm{susc}}}{\gamma}} S(0)\right) + 1} \, .
\end{aligned}
\tag{S74}
$$

This can be integrated, to give

$$
\begin{aligned}
R_\infty &= R(0) + \int_{I(0)}^{I_\infty} \frac{\gamma}{\beta S - \gamma} \, \mathrm{d}I \tag{S75} \\
&= R(0) + \int_{I(0)}^{I_\infty} \frac{-1}{W_i\left(-\frac{\beta}{\gamma} e^{\frac{\beta}{\gamma}(I - I(0) - S(0))} \left(\frac{I}{I(0)}\right)^{\frac{\phi_{\mathrm{susc}}}{\gamma}} S(0)\right) + 1} \, \mathrm{d}I \\
&= \int_0^{I(0)} \frac{1}{W_i\left(-\frac{\beta}{\gamma} e^{\frac{\beta}{\gamma}(I - I(0) - S(0))} \left(\frac{I}{I(0)}\right)^{\frac{\phi_{\mathrm{susc}}}{\gamma}} S(0)\right) + 1} \, \mathrm{d}I \, , \tag{S76}
\end{aligned}
$$

where the appropriate branch of W_i is determined as above, as the integration varible I is varied. Note, however, that the integral in Equation (S75) is improper, because the integral diverges at the peak prevalence (when $S = \gamma/\beta$).

E.4 Instantaneous vaccination of a proportion ϕ_{inst} of the population

In this case, the disease progresses according to the standard SIR model,

$$
\begin{aligned}
\dot{S} &= -\beta S I \, , \tag{S77a} \\
\dot{I} &= (\beta S - \gamma) I \, , \tag{S77b} \\
\dot{R} &= \gamma I \, , \tag{S77c}
\end{aligned}
$$

with initial conditions given by

$$
\begin{aligned}
S(0) &= (1 - p)(1 - \alpha)(1 - \phi_{\mathrm{inst}}) \\
I(0) &= (1 - p)\alpha \\
R(0) &= 0 \\
V(0) &= p + \phi_{\mathrm{inst}}(1 - p)(1 - \alpha) \, .
\end{aligned}
$$

Note that for this model, $S(0)$ is the density of susceptibles after the post-outbreak vaccination response has taken place.

18

Equation (S77a) implies that

$$-\frac{\gamma}{\beta}\frac{\mathrm{d}}{\mathrm{d}t}\ln(S) = \dot{R}\,, \tag{S78}$$

thus S_∞ satisfies the equation

$$\frac{\gamma}{\beta}\ln\left(\frac{S(0)}{S_\infty}\right) = R_\infty = 1 - V(0) - S_\infty\,, \tag{S79}$$

or

$$S_\infty = -\frac{\gamma}{\beta}\,W_0\left(-\frac{\beta}{\gamma}S(0)e^{-\frac{\beta}{\gamma}(1-V(0))}\right)\,. \tag{S80}$$

We use the principle branch of the Lambert function in order to obtain solutions satisfying $S_\infty \le S(0)$. Since $-\frac{\beta}{\gamma}S(0)e^{-\frac{\beta}{\gamma}(1-V(0))} > -\frac{\beta}{\gamma}S(0)e^{-\frac{\beta}{\gamma}S(0)}$, and W_1 is monotonically decreasing, $-\frac{\gamma}{\beta}W_1\left(-\frac{\beta}{\gamma}S(0)e^{-\frac{\beta}{\gamma}(1-V(0))}\right) > S(0)$, which does not correspond to biologically feasible solutions. In addition, we have $R_\infty = \frac{\gamma}{\beta}\ln\frac{S(0)}{S_\infty}$.

Since there is no vaccination except during the initial (immediate) response to the outbreak, $V_\infty = V(0) = p + \phi_{\mathrm{inst}}(1-p)(1-\alpha)$, and so

$$\psi_p = \frac{V_\infty - p}{1 - p} = \phi_{\mathrm{inst}}(1-\alpha) \tag{S81a}$$

$$\pi_p = 1 - \psi_p - \frac{S_\infty}{1 - p}\,. \tag{S81b}$$

Using Equation (S79), we also have

$$\pi_p = -\frac{\gamma}{\beta(1-p)}\ln\left(\frac{1 - \pi_p - \phi_{\mathrm{inst}}(1-\alpha)}{(1-\alpha)(1-\phi_{\mathrm{inst}})}\right) \tag{S82}$$

It follows from Equation (S81b) that π_p is a decreasing function of p: from Equation (S79) we have

$$\frac{\gamma}{\beta}\left(-\frac{1}{1-p} - \frac{\partial_p S_\infty}{S_\infty}\right) = -1 + \phi_{\mathrm{inst}}(1-\alpha) - \partial_p S_\infty \tag{S83}$$

and so

$$\partial_p S_\infty = \left(-1 + \phi_{\mathrm{inst}}(1-\alpha) + \frac{\gamma}{\beta}\frac{1}{1-p}\right)\left(\frac{\beta S_\infty}{\beta S_\infty - \gamma}\right)\,. \tag{S84}$$

This gives

$$(1-p)\partial_p S_\infty + S_\infty = \frac{\beta S_\infty}{\beta S_\infty - \gamma}\left((1-p)\left(-1 + \phi_{\mathrm{inst}}(1-\alpha)\right) + S_\infty\right)$$

$$= \frac{\beta S_\infty}{\gamma - \beta S_\infty}\left(1 - V_\infty - S_\infty\right)\,, \tag{S85}$$

which is positive so long as $R_\infty > 0$ (this happens when $S(0) > S_\infty$, which is true whenever $S(0)$ and $I(0)$ are not 0). It now follows that $\partial_p \pi_p = -\frac{(1-p)\partial_p S_\infty + S_\infty}{(1-p)^2} < 0$. Note that the probability of a delayer being vaccinated post-outbreak (ψ_p) is constant.

Lastly, note that

$$(1-p)\partial_p S_\infty = \left(1 - V_\infty - \frac{\gamma}{\beta}\right)\left(\frac{\beta S_\infty}{\gamma - \beta S_\infty}\right), \tag{S86}$$

which implies that S_∞ increases with p *iff* $(1-p)(1 - \phi_{\text{inst}}(1-\alpha))\beta > \gamma$, or equivalently, $I(0) + S(0) = 1 - V_\infty > \frac{\gamma}{\beta}$. Compare this to the more stringent condition $S(0) > \frac{\gamma}{\beta}$ which ensures that the epidemic takes off ($I'(0) > 0$).

F Maximal vaccination rate for fair comparison of models

In this section, we find the fair comparison values of the vaccination efforts ϕ_{inc} and ϕ_{prev} (see §6.2). These are defined as the levels of vaccination effort ϕ_{inc} and ϕ_{prev} that result in maximal vaccination rates equal to 0.1/day (that is, comparable to [7]).

F.1 Maximal Vaccination rate when $\dot{V} = \phi_{\text{prev}}I$

We begin by finding what the maximal vaccination is when $\dot{V} = \phi_{\text{prev}}I$. Because the vaccination rate, $\dot{V}$, is maximal when prevalence, I, is maximal, we aim to find the maximal prevalence. Now observe that since $\dot{I} = (\beta S - \gamma)I$, incidence is maximal when $S = \gamma/\beta$. Thus, the peak prevalence is found by substituting $S = \gamma/\beta$, into Equation (S21) to obtain

$$I_{\text{peak}} = 1 - p - \gamma/\beta + \frac{\gamma + \phi_{\text{prev}}}{\beta}\ln\left(\frac{\gamma + \phi_{\text{prev}}}{\beta S(0) + \phi_{\text{prev}}}\right) \tag{S87}$$

(recall that $I(0) + S(0) = 1 - p$). We now wish to find at which value of p the maximal vaccination rate (over time) is largest. Observe that

$$\frac{\partial}{\partial p}I_{\text{peak}} = -1 + \frac{(\gamma + \phi_{\text{prev}})(1-\alpha)}{\beta S(0) + \phi_{\text{prev}}}, \tag{S88}$$

$$\frac{\partial^2}{\partial p^2}I_{\text{peak}} = \frac{\beta(\gamma + \phi_{\text{prev}})(1-\alpha)^2}{(\beta S(0) + \phi_{\text{prev}})^2} > 0, \tag{S89}$$

which implies that the peak prevalence (and thus the maximal vaccination rate) has a minium in p when

$$p_{\text{crit}} = \frac{(\beta - \gamma)(1-\alpha) + \phi_{\text{prev}}\alpha}{\beta(1-\alpha)} > 0 \tag{S90}$$

($\beta > \gamma$ because $\mathcal{R}_0 > 1$).

There are now two possibilities:

20

- If $p_{\text{crit}} \geq 1$ (which happens *iff* $\phi_{\text{prev}}\alpha \leq \gamma(1-\alpha)$) then the maximal vaccination rate is attained when $p = 0$.

- If $p_{\text{crit}} < 1$ (which happens *iff* $\phi_{\text{prev}}\alpha > \gamma(1-\alpha)$) then, the maximal vaccination rate must be attained either when $p = 0$ or when $p = 1$.

Noting that

$$I_{\text{peak}}|_{p=0} = 1 - \gamma/\beta + \frac{\gamma + \phi_{\text{prev}}}{\beta} \ln\left(\frac{\gamma + \phi_{\text{prev}}}{\beta(1-\alpha) + \phi_{\text{prev}}}\right)$$

$$I_{\text{peak}}|_{p=1} = -\gamma/\beta + \frac{\gamma + \phi_{\text{prev}}}{\beta} \ln\left(\frac{\gamma + \phi_{\text{prev}}}{\phi_{\text{prev}}}\right), \tag{S91}$$

it follows that

$$\dot{V}_{\text{max}} = -\phi_{\text{prev}}\frac{\gamma}{\beta} + \phi_{\text{prev}} \max\left\{1 + \frac{\gamma + \phi_{\text{prev}}}{\beta} \ln\left(\frac{\gamma + \phi_{\text{prev}}}{\beta(1-\alpha) + \phi_{\text{prev}}}\right),\right.$$

$$\left.\frac{\gamma + \phi_{\text{prev}}}{\beta} \ln\left(\frac{\gamma + \phi_{\text{prev}}}{\phi_{\text{prev}}}\right)\right\}. \tag{S92}$$

We also note that

$$\frac{\partial}{\partial \phi_{\text{prev}}} I_{\text{peak}} = \frac{1}{\beta} \ln\left(\frac{\gamma + \phi_{\text{prev}}}{\beta S(0) + \phi_{\text{prev}}}\right) + \frac{1}{\beta}\left(1 - \frac{\gamma + \phi_{\text{prev}}}{\beta S(0) + \phi_{\text{prev}}}\right). \tag{S93}$$

Because $1 - x + \ln(x) < 0$ for any $0 < x \neq 1$, it follows that the peak prevalence I_{peak}, and thus the peak vaccination rate, decreases with increasing vaccination effort, ϕ_{prev} (for any initial coverage, p). Also, as $\phi_{\text{prev}} \to \infty$, we have

$$I_{\text{peak}}|_{p=0} \to \alpha\,,$$

$$I_{\text{peak}}|_{p=1} \to 0\,.$$

Setting $\dot{V}_{\text{max}} = 0.1/\text{day}$ in Equation (S92) we can numerically solve for ϕ_{prev}, with α, β, γ, as in Tables 1 and 2 to obtain $\phi_{\text{prev}} \approx 1582/\text{day}$.

F.2 Maximal Vaccination rate when $\dot{V} = \phi_{\text{inc}}SI$

First, we will derrive a formula for the maximal vaccination rate as it depends on the model parameters, α, β, γ, ϕ_{inc}. We then use this formula to calculate the appropriate range for ϕ_{inc}, given the estimates of the other parameters cited in Tables 1 and 2.

Differentiating Equation (S46d), we have

$$\ddot{V} = \phi_{\text{inc}}\left(\dot{S}I + S\dot{I}\right) = \phi_{\text{inc}}SI\left(\beta S - \gamma - (\beta + \phi_{\text{inc}})I\right).$$

Thus, critical points of $\dot{V}$ (excluding those for which $\dot{V} = 0$) occur when $\beta S - \gamma = (\beta + \phi_{\text{inc}})I$. Using Equation (S48) and simplifying, this is equivalent to

$$2\beta S = \gamma \ln S + \phi_{\text{inc}}(1-p)\alpha + \beta(1-p) + \gamma\left(1 - \ln\left((1-p)(1-\alpha)\right)\right),$$

21

which has two formal solutions,

$$\hat{S}_k = -\frac{\gamma}{2\beta} \, W_k \left(-2\frac{\beta}{\gamma}(1-p)(1-\alpha)e^{-\frac{\beta+\phi_{\text{inc}}\alpha}{\gamma}(1-p)-1} \right),$$

with $k = 0$ or -1.

However, it is impossible for $\hat{S}_0$ to be attained by $S(t)$, for all $t \geq 0$. To see this, suppose, in order to derive a contradiction, that there is some time $\hat{t}_0 \geq 0$ such that $S(\hat{t}_0) = \hat{S}_0$. Note that $-1 \leq W_0 < 0$ on the interval $[-1/e, 0)$, so $0 < \hat{S}_0 < \gamma/\beta$. Because $\hat{S}_0 < \gamma/\beta$, we have $\dot{I}(\hat{t}_0) < 0$. Since $\dot{S} < 0$ (for all time t), it follows that $\dddot{V} < 0$ when $t = \hat{t}_0$, in contradiction to the fact that by definition of $\hat{S}_0$, $\ddot{V}(\hat{t}_0) = 0$. Thus, $S(t) > \hat{S}_0$ is proven[1]. It follows that if there is a biologically relevant value of S at which $\ddot{V}$ changes signs, it must be

$$\hat{S}_{-1} = -\frac{\gamma}{2\beta} \, W_{-1} \left(-2\frac{\beta}{\gamma e}(1-p)(1-\alpha)e^{-\frac{\beta+\phi_{\text{inc}}\alpha}{\gamma}(1-p)} \right). \tag{S94}$$

Note that $\hat{S}_{-1} > \frac{\gamma}{2\beta}$ because $W_{-1}(x) < -1 \quad \forall x \in [-1/e, 0]$ (but it is also possible that $\hat{S}_{-1} > S(0) = (1-p)(1-\alpha)$, which would make this critical point biologically unfeasible).

Because S decreases with time, we see that $\ddot{V}$ can change signs at most once for all $t \geq 0$. Observe that since $0 < S_\infty < \gamma/\beta$, and $\dot{V}$ decreases when $S \in (0, \gamma/\beta]$, it follows that $\dot{V}$ eventually (*i.e.*, for large enough t) decreases with time. Hence, if $\ddot{V}(0) \leq 0$, then $t = 0$ is a maximum of $\dot{V}$ for $t \geq 0$, and if $\ddot{V}(0) > 0$ then $\dot{V}$ attains its maximum when $S(t) = \hat{S}_{-1}$. The sign of $\ddot{V}(0)$ is identical to the sign of $\beta S(0) - \gamma - (\beta + \phi_{\text{inc}})I(0)$, so the maximal vaccination rate is attained at $t = 0$ if $(1-p)\big((1-2\alpha)\beta - \alpha\phi_{\text{inc}}\big) \leq \gamma$, and when $S(t) = \hat{S}_{-1}$ otherwise. Thus,

$$\nu(p) = \max_{t \geq 0} \dot{V} = \begin{cases} \phi_{\text{inc}}(1-p)^2(1-\alpha)\alpha & \text{if } (1-p)((1-2\alpha)\beta - \alpha\phi_{\text{inc}}) \leq \gamma, \\ \frac{\phi_{\text{inc}}}{\phi_{\text{inc}}+\beta}(\beta\hat{S}_{-1} - \gamma)\hat{S}_{-1} & \text{if } (1-p)((1-2\alpha)\beta - \alpha\phi_{\text{inc}}) > \gamma, \end{cases} \tag{S95}$$

(where, for the second case, we used the fact that $I = \frac{\beta\hat{S}_{-1}-\gamma}{\phi_{\text{inc}}+\beta}$ when $S = \hat{S}_{-1}$).

To maximize ν over all $p \in [0, 1)$ (with α, β, γ and ϕ_{inc} fixed), we consider the following 3 cases:

- First, if $0 < \gamma < (1-2\alpha)\beta - \alpha\phi_{\text{inc}}$, then $(1-p)((1-2\alpha)\beta - \alpha\phi_{\text{inc}}) \leq \gamma$ is equivalent to $\hat{p} = 1 - \frac{\gamma}{(1-2\alpha)\beta - \alpha\phi_{\text{inc}}} \leq p$, and $\hat{p} \in (0, 1)$. Hence, for $p \in [\hat{p}, 1)$, $\nu(p) = \phi_{\text{inc}}(1-p)^2(1-\alpha)\alpha$ is a decreasing function of p, and so $\max_{p \in [\hat{p},1)} \nu(p) = \phi_{\text{inc}}\left(\frac{\gamma}{(1-2\alpha)\beta - \alpha\phi_{\text{inc}}}\right)^2(1-\alpha)\alpha$, and is attained when $p = \hat{p}$.

  When $0 \leq p < \hat{p}$, we note that because $(\beta x - \gamma)x$ is parabolic with a minimum at $x = \gamma/2\beta$, and $\hat{S}_{-1} \geq \frac{\gamma}{2\beta}$, it follows that

$$\nu(p) = \frac{\phi_{\text{inc}}}{\phi_{\text{inc}} + \beta}(\beta\hat{S}_{-1} - \gamma)\hat{S}_{-1} \tag{S96}$$

---

[1] Consequently, $S_\infty \geq \hat{S}_0$, which is equivalent to a statement about the Lambert W function: $W_0(2x/e) \geq 2\,W_0(x)$, for $-1/e < x < 0$.

22

is increasing in $\hat{S}_{-1}$, so $\max_{p \in [0,\hat{p}]} \nu(p)$ is attained on this interval when $\hat{S}_{-1}$ is maximized. Because $-\frac{\gamma}{2\beta} W_{-1}(x)$ is monotonically increasing, it follows that $\max_{p \in [0,\hat{p}]} \nu(p)$ is maximal when

$$-2\frac{\beta}{\gamma e}(1-p)(1-\alpha)e^{-\frac{\beta+\phi_{\text{inc}}\alpha}{\gamma}(1-p)}$$

is maximal. Consequently, we need to maximize $-axe^{-x}$ (with $a > 0$), with $x(p) = \frac{\beta+\phi_{\text{inc}}\alpha}{\gamma}(1-p)$, over the interval $0 \le p \le \hat{p}$. This corresponds to maximizing $-axe^{-x}$ over $[\frac{\beta+\phi_{\text{inc}}\alpha}{\gamma}, \frac{\beta+\phi_{\text{inc}}\alpha}{(1-2\alpha)\beta-\alpha\phi_{\text{inc}}}] \subset [1,\infty)$. Observe that $-axe^{-x}$ has a unique global minimum at $x = 1$, and in particular, it is increasing when $x \ge 1$. This implies that in the relevant range of x, $\hat{S}_{-1}$ increases with x, and thus decreases in p. It follows that $\hat{S}_{-1}$ is maximal when $p = 0$, and its value is

$$\hat{S}_{-1}|_{p=0} = -\frac{\gamma}{2\beta} W_{-1}\left(-2\frac{\beta}{\gamma e}(1-\alpha)e^{-\frac{\beta+\phi_{\text{inc}}\alpha}{\gamma}}\right). \tag{S97}$$

Thus, $\max_{p \in [0,1)} \nu(p) = \nu(0)$, and is attained when $p = 0$ (note also that $\nu(p)$ is continuous at $p = \hat{p}$).

- When $0 < (1-2\alpha)\beta - \alpha\phi_{\text{inc}} \le \gamma$, $(1-p)((1-2\alpha)\beta - \alpha\phi_{\text{inc}}) \le \gamma$ is equivalent to $\hat{p} = 1 - \frac{\gamma}{(1-2\alpha)\beta-\alpha\phi_{\text{inc}}} \le p$, which is satisfied for all $p \in [0,1)$, since $\hat{p} \le 0$. Thus, $\nu(p)$ is a decreasing function of p for all $p \in [0,1)$, and thus $\max_{p \in [0,1)} \nu(p) = \phi_{\text{inc}}(1-\alpha)\alpha$ is attained at $p = 0$.

- When $\alpha\phi_{\text{inc}} \ge (1-2\alpha)\beta$, then $(1-p)((1-2\alpha)\beta - \alpha\phi_{\text{inc}}) \le \gamma$ is always satisfied (since the left hand side is never positive, and $\gamma > 0$). Thus, $\nu(p) = \phi_{\text{inc}}(1-p)^2(1-\alpha)\alpha$, which decreases with p, so $\max_{p \in [0,1)} \nu(p) = \phi_{\text{inc}}(1-\alpha)\alpha$, and is attained at $p = 0$.

Rearranging the conclusions of the preceeding discussion, we see that

$$\max_{p \in [0,1), t \ge 0} \dot{V} = \begin{cases} \frac{\phi_{\text{inc}}}{\phi_{\text{inc}}+\beta}(\beta\hat{S}_{-1} - \gamma)\hat{S}_{-1}|_{p=0} & \text{if } 0 \le \alpha\phi_{\text{inc}} < (1-2\alpha)\beta - \gamma, \\ \alpha\phi_{\text{inc}}(1-\alpha) & \text{if } (1-2\alpha)\beta - \gamma \le \phi_{\text{inc}}\alpha. \end{cases} \tag{S98}$$

When $0 \le \alpha\phi_{\text{inc}} < (1-2\alpha)\beta - \gamma$, then $\max_{p \in [0,1), t \ge 0} \dot{V} = \frac{\phi_{\text{inc}}}{\phi_{\text{inc}}+\beta}(\beta\hat{S}_{-1} - \gamma)\hat{S}_{-1}|_{p=0}$, which increases as $S_{-1}|_{p=0}$ increases, as stated earlier. Since $-W_{-1}(x)$ increases with x, and $-2\frac{\beta}{\gamma e}(1-\alpha)e^{-\frac{\beta+\phi_{\text{inc}}\alpha}{\gamma}}$ is an increasing function of ϕ_{inc}, we conclude that in this range, $\max_{p \in [0,1), t \ge 0} \dot{V}$ increases with ϕ_{inc}. When $(1-2\alpha)\beta - \gamma \le \phi_{\text{inc}}\alpha$, $\max_{p \in [0,1)} \nu(p)$ manifestly increases linearly with ϕ_{inc}. In all, $\max_{p \in [0,1), t \ge 0} \dot{V}$ is a monotonically increasing function of ϕ_{inc}.

Note that at the point separating the two regimes, $\phi_{\text{inc}} = \frac{(1-2\alpha)\beta-\gamma}{\alpha} = 16570.71/\text{day}$, $\max_{p \in [0,1), t \ge 0} \dot{V} = ((1-2\alpha)\beta - \gamma)(1-\alpha) = 0.29/\text{day}$ (with parameters as in Table 1).

Finally, to obtain a value of ϕ_{inc} that yields a maximal vaccination rate of $\Phi = 0.1/\text{day}$ (as was estimated in [7]), we solve

$$\frac{\phi_{\text{inc}}}{\phi_{\text{inc}}+\beta}(\beta\hat{S}_{-1} - \gamma)\hat{S}_{-1}|_{p=0} = \Phi, \tag{S99}$$

23

which gives $\hat{S}_{-1}|_{p=0} = \frac{\gamma \pm \sqrt{\gamma^2 + 4\beta\Phi(1+\beta/\phi_{\text{inc}})}}{2\beta}$. We take the solution corresponding to the positive sign (the other one gives negative $\hat{S}_{-1}$, which is biologically absurd). Thus,

$$W_{-1}\left(-2\frac{\beta}{\gamma e}(1-\alpha)e^{-\frac{\beta+\phi_{\text{inc}}\alpha}{\gamma}}\right) = -1 - \sqrt{1 + 4\frac{\beta}{\gamma^2}\Phi(1+\beta/\phi_{\text{inc}})}, \qquad \text{(S100)}$$

which is equivalent to

$$\frac{2\beta(1-\alpha)}{\gamma\left(1+\sqrt{1+4\frac{\beta}{\gamma^2}\Phi(1+\beta/\phi_{\text{inc}})}\right)} = \exp\left(\frac{\beta+\phi_{\text{inc}}\alpha}{\gamma} - \sqrt{1+4\frac{\beta}{\gamma^2}\Phi(1+\beta/\phi_{\text{inc}})}\right),$$

which we solve numerically for ϕ_{inc}, with parameters as in Tables 1 and 2, to get $\phi_{\text{inc}} \approx$ 5190/day.

G   The individual equilibrium

In this section, we show that for each of the five models defined in § 5, the game defined in § 3 always has a unique convergently stable Nash equilibrium (defined in § 3 and abbreviated CSNE). The proofs given here are constructive, *i.e.,* they also provide a method for numerically finding the individual equilbrium (p_{i}).

G.1   Vaccination rate $\propto$ disease prevalence

In this scenario we have 3 cases to examine:

1. $p_m \geq 1$ ($\Longleftrightarrow \alpha\phi_{\text{prev}} \geq \gamma(1-\alpha)$)

2. $p_m \leq 1$ and $p_0 \leq 0$

3. $p_m \leq 1$ and $p_0 \in (0,1)$

Recall that in the first case, we have proven (in Appendix E.1) that π_p decreases with p. As stated in § 5.1, we assume that π_p decreases with p for the other two cases as well.

G.1.1 $p_m \geq 1$

In this case, we have a unique convergently stable Nash equilibrium (CSNE). To see this, note that $\psi_p + \pi_p = 1$ and $\partial_p \pi_p < 0$. Thus,

$$\Delta E = [\pi_p + (1-\pi_p)r - r/a]a(P-Q)$$
$$= [\pi_p a(1-r) - r(1-a)](P-Q)$$
$$= a(1-r)\left[\pi_p - \frac{r(1-a)}{a(1-r)}\right](P-Q). \qquad \text{(S101)}$$

24

It is convenient to define

$$\rho_1 = \frac{r(1-a)}{a(1-r)} = \frac{r}{1-r} \bigg/ \frac{a}{1-a}, \tag{S102}$$

which we can interpret as an **odds ratio**, namely the odds of a bad outcome from vaccination (compared with infection) relative to the odds of an outbreak occuring. The odds ratio is well-defined and strictly positive ($\rho_1 > 0$) because $0 < r < 1$ and $0 < a < 1$. Since π_p decreases monotonically with p, there are three cases:

- If $\pi_0 \leq \rho_1$ then $\pi_p < \rho_1$ $\forall p > 0$. It follows that $\forall \epsilon \in [0,1)$ $\Delta E > 0 \; \forall Q \neq P \iff P = 0$. Hence $p_\mathrm{i} = 0$ is the unique Nash equilibrium. Let $0 \leq P < Q$ and fix $\epsilon \in [0,1)$. It follows that $p > 0$, and so $\pi_p - \rho_1 < 0$. Thus $\Delta E > 0$ and p_i is convergently stable.

- If $\alpha = \pi_1 \geq \rho_1$, then $\pi_p > \rho_1$ $\forall p < 1$. It follows that $\forall \epsilon \in [0,1)$ $\Delta E > 0 \; \forall Q \neq P \iff P = 1$. Hence $p_\mathrm{i} = 1$ is the unique Nash equilibrium. The condition translates to $r(1-a) < \alpha a(1-r)$, or $r_\mathrm{v} < ar_\mathrm{i}\alpha + ar_\mathrm{v}(1-\alpha)$. Recall that if an outbreak occurs, at the end of the epidemic individuals have either been vaccinated or have contracted the disease. Thus the right hand side is the risk to a vaccinator, and the left hand side is the minimal possible risk to a delayer (assuming no-one is infected after the initial outbreak; if there are secondary infections, then because $r_\mathrm{v} < r_\mathrm{i}$, the delayer's risk can only be increased). Let $1 \geq P > Q$ and fix $\epsilon \in [0,1)$. It follows that $p < 1$, and so $\pi_p - \rho_1 > 0$. Thus $\Delta E > 0$ and p_i is convergently stable.

- If $\pi_0 > \rho_1 > \pi_1 = \alpha$ then there is a unique $\tilde{p} \in (0,1)$ such that $\pi_p - \rho_1 > 0$ if $p < \tilde{p}$, $\pi_{\tilde{p}} = \rho_1$ and $\pi_p - \rho_1 < 0$ if $p > \tilde{p}$. Now since for any $\epsilon \in [0,1)$, $Q < P \implies p < P$ and $Q > P \implies p > P$, we have $\forall \epsilon \in [0,1)$ $\Delta E > 0 \; \forall Q \neq P \iff P = \tilde{p}$ (for other P take Q between P and $\tilde{p}$). Thus, the unique Nash equilibrium p_i is the unique solution to $\pi_{p_\mathrm{i}} = \rho_1$. Fix $\epsilon \in [0,1)$. If $Q < P \leq p_\mathrm{i}$, $Q \leq p < P \leq p_\mathrm{i}$. Thus $\pi_p - \rho_1 > 0 \implies \Delta E > 0$. Similarly, If $Q > P \geq p_\mathrm{i}$, $Q \geq p > P \geq p_\mathrm{i}$. Thus $\pi_p - \rho_1 < 0 \implies \Delta E > 0$. Hence p_i is convergently stable.

  Now, to find $\tilde{p}$: recall that $1 - \pi_p = \frac{\phi_{\mathrm{prev}}}{\beta(1-p)} \ln\left(\frac{\beta}{\phi_{\mathrm{prev}}}(1-\alpha)(1-p) + 1 \right)$ and thus

$$\tilde{p} = 1 + \phi_{\mathrm{prev}} \frac{(1-\rho_1) + (1-\alpha)\, W\left(-\frac{1-\rho_1}{1-\alpha} e^{-\frac{1-\rho_1}{1-\alpha}} \right)}{(1-\alpha)\beta(1-\rho_1)}. \tag{S103}$$

  Again, W is applied to a negative argument, and it is necessary to determine which branch of W to use. The principal branch gives $\tilde{p} = 1$, and $\pi_p \to \alpha$ as $p \to 1$, and $\rho_1 > \alpha$ by assumption, and so by elimination we must use W_{-1}. Interestingly, $\tilde{p}$ depends linearly on ϕ_{prev}. Recall that $W_{-1} \leq -1$, and so $\frac{\partial \tilde{p}}{\partial \phi_{\mathrm{prev}}} < 0$.

Thus, in all three cases there exists a unique CNSE.

G.1.2 $\quad p_m \leq 1$ **and** $p_0 \leq 0$

637 In the 2nd case, recall that $\psi_p = \frac{\phi_{\text{prev}}}{\gamma}\pi_p$, and let

638
$$\rho_2 = \frac{r}{a(1 + r\phi_{\text{prev}}/\gamma)} , \tag{S104}$$

639 to obtain

640
$$\Delta E = [\pi_p + \frac{\phi_{\text{prev}}}{\gamma}\pi_p r - r/a]a(P - Q)$$

641
$$= [\pi_p a(1 + \frac{\phi_{\text{prev}}}{\gamma}r) - r](P - Q)$$

642
$$= a(1 + \frac{\phi_{\text{prev}}}{\gamma}r)[\pi_p - \frac{\gamma r}{a(r\phi_{\text{prev}} + \gamma)}](P - Q)$$

643
$$= a(1 + \frac{\phi_{\text{prev}}}{\gamma}r)[\pi_p - \rho_2](P - Q) . \tag{S105}$$

644

645 Now recall that π_p decreases with p. So, an identical argument to the one in Ap-
646 pendix G.1.1 also applies here:

647 • If $\pi_0 \leq \rho_2$ then $\pi_p < \rho_2 \quad \forall p > 0$. Thus, $\forall \epsilon \in [0,1) \quad \Delta E > 0 \, \forall Q \neq P \iff P = 0$.
648   Hence $p_i = 0$ is the unique Nash equilibrium. Let $0 \leq Q < P < 1$ and fix $\epsilon \in [0,1)$. It
649   follows that $p > 0$, and so $\pi_p - \rho_2 < 0$. Thus $\Delta E > 0$ and p_i is convergently stable.

650 • If $\alpha = \pi_1 \geq \rho_2 \geq 0$, then $\pi_p > \rho_2 \quad \forall p < 1$. It follows that $\forall \epsilon \in [0,1) \quad \Delta E > 0 \, \forall Q \neq$
651     $P \iff P = 1$. Hence $p_i = 1$ is the unique Nash equilibrium. Let $1 \geq P > Q$ and
652   fix $\epsilon \in [0,1)$. It follows that $p < 1$, and so $\pi_p - \rho_2 > 0$. Thus $\Delta E > 0$ and p_i is
653   convergently stable.

654 • If $\pi_0 > \rho_2 > \pi_1 = \alpha$ then there is a unique $\tilde{p} \in (0,1)$ such that $\pi_p - \rho_2 > 0$ if $p < \tilde{p}$,
655     $\pi_{\tilde{p}} = \rho_2$ and $\pi_p - \rho_2 < 0$ if $p > \tilde{p}$. Now since for any $\epsilon \in [0,1)$, $Q < P \implies p < P$
656   and $Q > P \implies p > P$, we have $\forall \epsilon \in [0,1) \quad \Delta E > 0 \, \forall Q \neq P \iff P = \tilde{p}$.
657   Thus, the unique Nash equilibrium p_i is the unique solution to $\pi_{p_i} = \rho_2$. Fix $\epsilon \in [0,1)$.
658   If $Q < P \leq p_i$, $Q \leq p < P \leq p_i$. Thus $\pi_p - \rho_2 > 0 \implies \Delta E > 0$. Similarly,
659   If $Q > P \geq p_i$, $Q \geq p > P \geq p_i$. Thus $\pi_p - \rho_2 < 0 \implies \Delta E > 0$. Hence p_i is
660   convergently stable.

To find $\tilde{p}$, recall that $R^1_\infty = (1-p)\pi_p$. Furthermore, from Equation (S27), we have

$$R^1_\infty = \frac{\gamma}{\beta} \ln \left(\frac{\beta S(0) + \phi_{\text{prev}}}{\beta S^1_\infty + \phi_{\text{prev}}} \right)$$

$$S^1_\infty = 1 - p - \frac{\phi_{\text{prev}} + \gamma}{\gamma} R^1_\infty$$

$$\Downarrow$$

$$R^1_\infty = \frac{\gamma}{\beta} \ln \left(\frac{\beta S(0) + \phi_{\text{prev}}}{\beta(1 - p - \frac{\phi_{\text{prev}}+\gamma}{\gamma} R^1_\infty) + \phi_{\text{prev}}} \right)$$

$$\Downarrow$$

$$(1-p)\pi_p = \frac{\gamma}{\beta} \ln \left(\frac{\beta S(0) + \phi_{\text{prev}}}{\beta(1-p)\left(1 - \frac{\phi_{\text{prev}}+\gamma}{\gamma}\pi_p\right) + \phi_{\text{prev}}} \right) .$$

Substituting $p = \tilde{p}$, and using $\pi_{\tilde{p}} = \rho_2 = \frac{\gamma r}{a(r\phi_{\text{prev}}+\gamma)}$, we obtain after minor rearrangement

$$\frac{\beta(1-\tilde{p})r}{a(r\phi_{\text{prev}}+\gamma)} = \ln \left(\frac{a(\beta(1-\tilde{p})(1-\alpha) + \phi_{\text{prev}})(r\phi_{\text{prev}}+\gamma)}{\beta(1-\tilde{p})(\gamma(a-r) - (1-a)r\phi_{\text{prev}}) + \phi_{\text{prev}}a(r\phi_{\text{prev}}+\gamma)} \right) . \tag{S106}$$

However, we have not succeeded in obtaining an analytical solution for the individual equilibrium from this equation.

Thus, in all three cases there exists a unique CSNE.

G.1.3 $p_m \le 1$ and $p_0 \in (0,1)$

Since π_p decreases with p, the argument above shows that there is a unique CSNE in each of the the two intervals $[0, p_0]$ and $[p_0, 1]$, denoted $P_{I,1}$ and $P_{I,2}$, respectively. These are the only candidates for Nash equilibria in the interval $[0, 1]$: Adding the two sub-intervals together amounts to adding more strategies to the game. Thus, a strategy which was a Nash equilibrium in one of the sub-intervals may not be a Nash equilibrium for the larger strategy set (because players now have a larger strategy set to choose from). However, a strategy which is a Nash equilibrium for $[0, 1]$ must be a Nash equilibrium in any sub-interval of $[0, 1]$ which contains it. The situation for convergent stability is a bit more subtle, and is considered below.

Note that when $p \ne p_0$,

$$\text{sgn}(\Delta E) = \text{sgn}\left((\pi_p - \rho(p))(P - Q) \right) \tag{S107}$$

where

$$\rho(p) = \begin{cases} \rho_1 & \text{if } p < p_0, \\ \rho_2 & \text{if } p \ge p_0 . \end{cases} \tag{S108}$$

27

Note also that

$$\pi_{p_0} = \rho_1 \iff r = \frac{\gamma a}{\phi_{\text{prev}}(1-a) + \gamma} \iff \pi_{p_0} = \rho_2\,. \tag{S109}$$

This may seem slightly perplexing at first, but recall that $\pi_{p_0} = \frac{\gamma}{\phi_{\text{prev}} + \gamma}$. Thus, if it so happens that $\pi_{p_0} = \rho_1$ or $\pi_{p_0} = \rho_2$, r and a must be related so that in fact $\rho_1 = \rho_2$.

We must now check a number of cases:

1. $\pi_0 \leq \rho_1$ and $\pi_{p_0} < \rho_2$: In this case, $\pi_p < \rho(p) \quad \forall p \in (0,1]$, and $P_{I,1} = 0$ and $P_{I,2} = p_0$. But if $P = p_0$ and $Q \in [0, p_0)$, $\Delta E < 0$ and so $P = p_0$ cannot be a Nash equilibrium. However, if $P = 0$, then $\forall \epsilon \in [0,1) \quad \Delta E > 0 \;\forall Q \neq P$, and so $P = 0$ is a Nash equilibrium. This is trivial for $Q \leq p_0$. For $p_0 < Q$, we have $\pi_p - \rho(p) < 0$ and $P - Q < 0$, so $\Delta E > 0$ as required. For convergent stability, we only need to check that if $0 < P < p_0 < Q \leq 1$, then for any $\epsilon \in [0,1)$ we have $\Delta E > 0$. In this case, $p \in [P, Q]$, and $P - Q < 0$. Furthermore, $\pi_p - \rho_1 < 0$ for any $p \leq p_0$, and $\pi_p - \rho_2 < 0$ for any $p \geq p_0$. But since $\pi_{p_0} - \rho_2 < 0$, $\pi_{p_0} - \rho_1 = 0$ is impossible and from continuity, $\pi_p - \rho_1 < 0$. Thus, $\Delta E(P, Q, \epsilon) > 0$ as required for convergent stability.

2. $\pi_0 \leq \rho_1$ and $\pi_{p_0} > \rho_2 > \pi_1 = \alpha$: In this case, $P_{I,1} = 0$ and $P_{I,2} \in (p_0, 1)$. Since $P_{I,1} = 0$ is a CSNE in $[0, p_0]$, we know that for any $\epsilon \in [0,1)$ and $0 < P < Q \leq p_0$, $\Delta E > 0$. In particular, for $\epsilon = 0$, and $0 < P < Q = p_0$ we get $[\pi_{p_0} + \psi_{p_0} r - r/a] = \frac{\Delta E}{(P-Q)} < 0$. But, from $P_{I,2} \in (p_0, 1)$ we can similarly get (for $\epsilon = 0$, $p_0 = Q < P < P_{I,2}$) $[\pi_{p_0} + \psi_{p_0} r - r/a]a = \frac{\Delta E}{(P-Q)} > 0$, a contradiction.

3. $\pi_0 \leq \rho_1$ and $\alpha = \pi_1 \geq \rho_2 > 0$: Here, $P_{I,1} = 0$ and $P_{I,2} = 1$. Since $P_{I,1} = 0$ is a CSNE in $[0, p_0]$, $\forall \epsilon \in [0,1)$ and $0 \leq P < Q \leq p_0$, $\Delta E > 0$. In particular, for $\epsilon = 0$, and $0 < P < Q = p_0$ we get $[\pi_{p_0} + \psi_{p_0} r - r/a] = \frac{\Delta E}{(P-Q)} < 0$. Similarly, since $P_{I,2} = 1$ is a CSNE in $[p_0, 1]$, $\forall \epsilon \in [0,1)$ and $p_0 \leq Q < P \leq 1$, $\Delta E > 0$. In particular, for $\epsilon = 0$, and $p_0 = Q < P \leq 1$ we get $[\pi_{p_0} + \psi_{p_0} r - r/a] = \frac{\Delta E}{(P-Q)} > 0$, which is a contradiction.

4. $\rho_2 \geq \pi_{p_0} \geq \rho_1$: In this case, simple algebra gives $\rho_1 = \rho_2 = \pi_{p_0}$ and $P_{I,1} = p_0$ and $P_{I,2} = p_0$. Thus, it follows that p_0 is the unique CSNE in the interval $[0,1]$.

5. $\pi_{p_0} > \rho_1$ and $\alpha = \pi_1 \geq \rho_2$: In a manner analogous to the first case, here, $p_i = 1$ is the unique CSNE.

6. $\pi_{p_0} > \rho_1$ and $\pi_{p_0} > \rho_2 > \pi_1 = \alpha$: , $P_{I,1} = p_0$ and $P_{I,2} \in (p_0, 1)$. $P_{I,1} = p_0$ cannot be a Nash equilibrium since for $p_0 < Q < P_{I,2}$, and any $\epsilon \in [0,1)$, $\Delta E < 0$ since $P_{I,2}$ is the unique CSNE in $[p_0, 1]$. To show that $P_{I,2}$ is a Nash equilibrium, fix $\epsilon \in [0,1)$ and $P = P_{I,2}$ and let $Q < P_{I,2}$. Note that $\pi_p > \rho_1 \;\forall p \in [0, p_0]$ and that because π_p is decreasing and $\pi_{P_{I,2}} = \rho_2$, $\pi_p > \rho_2 \;\forall p < P_{I,2}$. Thus $\pi_p > \rho(p) \;\forall p < P_{I,2}$ and so in particular, $\Delta E > 0$ and $P_{I,2}$ is the unique Nash equilibrium. To see that $P_{I,2}$ is also convergently stable, we must only show that for any P and Q, $0 \geq Q < p_0 < P < P_{I,2}$ and $\epsilon \in [0,1)$, we have $\Delta E > 0$. But under these conditions, $p < P_{I,2}$ and so again $\pi_p > \rho(p)$, which implies $\Delta E > 0$, as required.

28

7. $\pi_0 > \rho_1 > \pi_{p_0}$ and $\pi_{p_0} < \rho_2$: Now, $P_{I,1} \in (0, p_0)$ and $P_{I,2} = p_0$. Similar to the above case, this implies that $P_{I,1}$ is the unique CSNE (given by Equation (S103)).

8. $\pi_0 > \rho_1 > \pi_{p_0}$ and $\alpha = \pi_1 \geq \rho_2$: Simple algebra shows that this case is impossible:

$$\rho_1 > \pi_{p_0} = \frac{\gamma}{\gamma + \phi_{\text{prev}}}$$

$$r(1-a)(\gamma + \phi_{\text{prev}}) > a(1-r)\gamma$$

$$r((1-a)\phi_{\text{prev}} + \gamma) > a\gamma$$

but

$$\rho_2 \leq \pi_1 < \pi_{p_0} = \frac{\gamma}{\gamma + \phi_{\text{prev}}}$$

$$r(\gamma + \phi_{\text{prev}}) < a(\phi_{\text{prev}}r + \gamma)$$

$$r((1-a)\phi_{\text{prev}} + \gamma) < a\gamma .$$

9. $\pi_0 > \rho_1 > \pi_{p_0}$ and $\pi_{p_0} > \rho_2 > \pi_1$: The reasoning applied to show that the case above is impossible also rules this case out.

We conclude that in all cases there is a unique CSNE, which we denote by p_{i}.

G.2   Vaccination rate $\propto$ incidence

Since $\partial_p \psi_p < 0$ and $\partial_p \pi_p < 0$, $\partial_p (\pi_p + r\psi_p) < 0$. Thus, an identical argument to the one given in Appendix G.3 allows us to show that there is always a CSNE for this model. In particular, there are three possibilities:

- If $\pi_0 + r\psi_0 \leq r/a$ then $p_{\text{i}} = 0$ is a unique CSNE.

- If $\alpha = \pi_1 + r\psi_1 \geq r/a$, then $p_{\text{i}} = 1$ is a unique CSNE.

- If $\pi_0 + r\psi_0 > r/a > \pi_1 + r\psi_1 = \alpha$ then there is a unique CSNE, $p_{\text{i}} \in (0, 1)$ such that $\pi_{p_{\text{i}}} + r\psi_{p_{\text{i}}} = r/a$. To simplify this last condition, we use Equations (S56) to obtain

$$0 = \pi_{p_{\text{i}}} + \psi_{p_{\text{i}}} r - \frac{r}{a} = \frac{a\left(\beta + r(1-\alpha)\phi_{\text{inc}}\right) - r(\beta + \phi_{\text{inc}})}{a(\beta + \phi_{\text{inc}})} - \frac{\beta + r\phi_{\text{inc}}}{\beta + \phi_{\text{inc}}} \frac{S_\infty}{1 - p_{\text{i}}}$$

which is equivalent to

$$\frac{S_\infty}{1 - p_{\text{i}}} = \frac{a\left(\beta + \alpha\phi_{\text{inc}} + r(1-\alpha)\phi_{\text{inc}}\right) - r(\beta + \phi_{\text{inc}})}{a(\beta + r\phi_{\text{inc}})} . \tag{S110}$$

Plugging Equation (S110) into Equation (S50) and rearranging gives the individual equilibrium,

$$p_{\text{i}} = 1 + \frac{a\gamma(\beta + r\phi_{\text{inc}})}{r(\beta + \phi_{\text{inc}})(\beta + a\alpha\phi_{\text{inc}})}$$

$$\times \ln\left(\frac{a\left(\beta + \alpha\phi_{\text{inc}} + r(1-\alpha)\phi_{\text{inc}}\right) - r(\beta + \phi_{\text{inc}})}{a(1-\alpha)(\beta + r\phi_{\text{inc}})}\right) . \tag{S111}$$

29

G.3 Vaccination rate $\propto$ proportion still susceptible

Recall that for this model, $\psi_p = 1 - \pi_p$ (see Appendix E.3) and that we assume π_p decreases with p (as stated in §5.2). Thus, $\partial_p (\pi_p + r\psi_p) = \partial_p ((1-r)\pi_p) < 0$, and we can infer that:

- If $\pi_0 + r\psi_0 \leq r/a$ then $\pi_p + r\psi_p < r/a \quad \forall p > 0$. Hence $p_i = 0$ is the unique Nash equilibrium. From reasoning similar to that given in Appendix G.1.1, p_i is convergently stable.

- If $\alpha = \pi_1 + r\psi_1 \geq r/a$, then $\pi_p + r\psi_p > r/a \quad \forall p < 1$. It follows that $p_i = 1$ is the unique Nash equilibrum and that it is convergently stable. The condition is equivalent to $a\alpha r_i \geq r_v$, which is quite intuitive: $a\alpha r_i$ is a lower bound on the cost for a delayer (attained when there are no new cases after the initial outbreak). If even this lower bound is higher than the cost of vaccinating, then clearly everyone should vaccinate.

- If $\pi_0 + r\psi_0 > r/a > \pi_1 + r\psi_1 = \alpha$ then there is a unique CSNE, $p_i \in (0,1)$ such that $\pi_{p_i} + r\psi_{p_i} = r/a$.

Thus, there is always a CSNE for this model.

G.4 Instantaneous vaccination of a proportion ϕ_{inst} of the population

In this case, $\psi_p = \phi_{\text{inst}}(1-\alpha)$ and $\pi_p = 1 - \psi_p - \frac{S_\infty}{1-p}$. Thus,

$$\Delta E = [\pi_p + \phi_{\text{inst}}(1-\alpha)r - r/a]a(P - Q). \tag{S112}$$

Letting $\rho = r/a - r\phi_{\text{inst}}(1-\alpha)$, since π_p decreases monotonically with p, we can use an argument similar to those used for the models considered above to show that:

- if $\pi_0 \leq \rho$ the $p_i = 0$ is the unique CSNE.

- if $\pi_1 \geq \rho$ then $\pi_p > \rho$ for any $p \in [0,1)$ and so $p_i = 1$ is the unique CSNE. Rearranging the condition $\pi_1 \geq \rho$ gives $a\alpha + ra\phi_{\text{inst}}(1-\alpha) \geq r$. This admits a simple biological interpretation: $a\alpha + ra\phi_{\text{inst}}(1-\alpha)$ is the relative risk of delaying when the epidemic does not successfully spread (that is, one can only be infected during the initial outbreak). Thus, if the risks of delaying are greater than vaccinating even if the disease does not spread beyond the cohort initially infected in the outbreak, then it is worthwhile for individuals to vaccinate pre-emptively.

- if $\pi_0 > \rho > 0$ then there is a unique CSNE, $p_i \in (0,1)$ such that $\pi_{p_i} = \rho$. In order to find p_i explicitly, we use Equation (S82) and substitute $\pi_{p_i} = r/a - r\phi_{\text{inst}}(1-\alpha)$:

$$r/a - r\phi_{\text{inst}}(1-\alpha) = -\frac{\gamma}{\beta(1-p_i)} \ln\left(\frac{1 - r/a - (1-r)\phi_{\text{inst}}(1-\alpha)}{(1-\alpha)(1-\phi_{\text{inst}})}\right),$$

and consequently,

$$p_i = 1 + \frac{a\gamma}{r\beta(1 - a\phi_{\text{inst}}(1-\alpha))} \ln\left(\frac{a(1 - (1-r)\phi_{\text{inst}}(1-\alpha)) - r}{a(1-\alpha)(1-\phi_{\text{inst}})}\right). \tag{S113}$$

30

G.5   constant rate vaccination

794   As in [7], we assume π_p is a decreasing function of p. The analysis (performed originally
795   in [7]) is then identical to Appendix G.1.1, implying the existence of a unique CSNE, which
796   we denote by p_i. Using the definition of ρ_1 given in Equation (S102), we have

797   • if $\pi_1 \geq \rho_1$ then $p_i = 1$.

798   • if $\pi_1 < \rho_1 < \pi_0$ then p_i is the unique solution of $\pi_{p_i} = \rho_1$

799   • if $\rho_1 \geq \pi_0$ then $p_i = 0$.

H   The group optimum

801   We have obtained an analytical formula for the group optimum (defined in § 4), for one
802   sub-case of one of our models. The calculation is given below.

H.1   Vaccination rate $\propto$ disease prevalence

804   We consider the case when $p_m \geq 1$. Recall that if $p_m \geq 1$, then $S_\infty = 0$, $\psi_p = \frac{\phi_{\text{prev}}}{\beta(1-p)} \ln\left(\frac{\beta}{\phi_{\text{prev}}} S(0) + 1\right)$,
805   and $\pi_p = 1 - \psi_p$ (see Appendix E.1). Thus,

$$C(p) = rp + (1-p)a(1 - (1-r)\psi_p)$$

$$= rp + (1-p)a\left(1 - (1-r)\frac{\phi_{\text{prev}}}{\beta(1-p)} \ln\left(\frac{\beta}{\phi_{\text{prev}}} S(0) + 1\right)\right)$$

$$= rp + a\left((1-p) - (1-r)\frac{\phi_{\text{prev}}}{\beta} \ln\left(\frac{\beta}{\phi_{\text{prev}}} S(0) + 1\right)\right)$$

$$C(0) = a\left(1 - (1-r)\frac{\phi_{\text{prev}}}{\beta} \ln\left(\frac{\beta}{\phi_{\text{prev}}}(1-\alpha) + 1\right)\right)$$

$$C(1) = r$$

$$C'(p) = r + a\left(-1 - (1-r)\frac{\phi_{\text{prev}}}{\beta}\left(-\frac{\beta}{\phi_{\text{prev}}}(1-\alpha)\right)\frac{1}{\frac{\beta}{\phi_{\text{prev}}} S(0) + 1}\right)$$

$$= r + a\left(\frac{\phi_{\text{prev}}(1-\alpha)(1-r)}{\beta S(0) + \phi_{\text{prev}}} - 1\right) \tag{S114}$$

814   Note that $C'(p)$ increases with p since $S(0)$ decreases with p and critical points of $C(p)$ are
815   minima. Thus, if there is a critical point within $[0,1]$, then it is the global minimum; other-
816   wise, the global minimum is at $C(0)$. To find critical points, set $C'(p) = 0$ or equivalently,

$$\frac{r}{a} = 1 - \frac{\phi_{\text{prev}}(1-\alpha)(1-r)}{\beta S(0) + \phi_{\text{prev}}} \tag{S115}$$

818   which can only happen if $r < a$ (since $\alpha < 1$ and $r < 1$), that is, the relative risk (of
819   vaccination *versus* infection) is less than the probability of an outbreak. If $r \geq a$ then

$C'(p) \geq 0$ throughout $[0, 1]$ and the minimal group cost $C(p)$ is attained at $p_{\mathrm{g}} = 0$. This is easily explained: If $r_{\mathrm{v}} \geq ar_{\mathrm{i}}$ then the mortality risks from vaccination are no less than those of dying in an outbreak. In this case, vaccinating is not worthwhile for either the individual or the group. We now solve Equation (S115) for the initial coverage p at the critical point of the group cost, $C(p)$, assuming $r < a$:

$$\beta S(0) = \frac{\phi_{\mathrm{prev}}(1 - \alpha)a(1 - r)}{a - r} - \phi_{\mathrm{prev}}$$

$$1 - p = \frac{\phi_{\mathrm{prev}}}{\beta(1 - \alpha)} \left(\frac{(1 - \alpha)a(1 - r)}{a - r} - 1 \right)$$

$$p = 1 - \frac{\phi_{\mathrm{prev}}}{\beta(1 - \alpha)} \left(\frac{(1 - a)r - (1 - r)\alpha a}{a - r} \right) \tag{S116}$$

The critical point is attained at $p \geq 1$ if and only if $(1 - a)r \leq (1 - r)\alpha a$, which is equivalent to

$$r_{\mathrm{v}} \leq a(r_{\mathrm{i}}\alpha + r_{\mathrm{v}}(1 - \alpha)), \tag{S117}$$

and in this case the group optimum is vaccinating the entire population ($p_{\mathrm{g}} = 1$). Biologically, Equation (S117) means that more people are expected to die if, in case of an outbreak, all individuals not infected initially are vaccinated (discounted by the outbreak probability, a), than the number of people expected to die if the entire population is vaccinated pre-emptively. To see this, note the probability of death due to vaccinating is r_{v} (the left hand side of Equation (S117)). To interpret the right hand side of Equation (S117), consider an individual who is not vaccinated pre-emptively. If there is an outbreak (represented by the factor a), the first term in brackets ($r_{\mathrm{i}}\alpha$) represents the probability of being in the initially infected cohort (α), and then dying due to the disease. The second term ($r_{\mathrm{v}}(1 - \alpha)$), represents the probability of not being in the initially infected cohort, and dying due to the vaccine side effects. Note that because in this scenario $S_\infty = 0$, no delayers remain susceptible (they are either infected or vaccinated). Thus, any individual who is not pre-emptively vaccinated, and who is not in the initially infected cohort ($1 - \alpha$) has either a probability r_{v} of dying due to vaccine side effects, or a probability r_{i} of dying due to the disease. But since $r_{\mathrm{v}} < r_{\mathrm{i}}$, the term $r_{\mathrm{v}}(1 - \alpha)$ is a lower bound on the probability of death for an individual who is susceptible immediately after the outbreak is seeded (that is, not pre-emptively vaccinated, or in the cohort initially infected at the beginning of the outbreak).

Note that not vaccinating anyone pre-emptively is the group optimum ($p_{\mathrm{g}} \leq 0$) *iff*

$$\beta(1 - \alpha)(a - r) \leq \phi_{\mathrm{prev}}((1 - a)r - (1 - r)\alpha a), \tag{S118}$$

(but this condition is difficult to interpret biologically).

Lastly, if $\phi_{\mathrm{prev}} \leq \beta \frac{(a - r)(1 - \alpha)}{r(1 - a(1 - \alpha)) - a\alpha}$ and $(1 - a)r > (1 - r)\alpha a$, then $p_{\mathrm{g}} \in [0, 1)$ and is given by Equation (S116). It is thus interesting to note that p_{g} depends piece-wise linearly on ϕ_{prev}.

References

[1] Kermack WO, McKendrick AG. A contribution to the mathematical theory of epidemics. Proceedings of the Royal Society of London Series A. 1927;115:700–721.

[2] Ma J, Earn DJD. Generality of the final size formula for an epidemic of a newly invading infectious disease. *Bulletin of Mathematical Biology*. 2006;68(3):679–702.

[3] Earn DJD, Andrews PW, Bolker BM. Population-level effects of suppressing fever. Proc R Soc Lond B. 2014;281(1778):20132570.

[4] Weisstein EW. Lambert W-Function. From MathWorld –A Wolfram Web Resource. http://mathworld.wolfram.com/LambertW-Function.html;.

[5] Corless RM, Gonnet GH, Hare DEG, Jeffrey DJ, Knuth DE. On the Lambert W function. Advances in Computational Mathematics. 1996;5(4):329–359.

[6] Hirsch MW, Smale S. Differential equations, dynamical systems, and linear algebra. Academic Press, New York; 1974.

[7] Bauch CT, Galvani AP, Earn DJD. Group interest versus self-interest in smallpox vaccination policy. *PNAS – Proceedings of the National Academy of Sciences of the U.S.A.*. 2003;100(18):10564–10567.